


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T13:52:41Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12406194" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12406194</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" xml:lang="en" id="a424041973" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Med Chem</journal-id><journal-id journal-id-type="iso-abbrev">J Med Chem</journal-id><journal-id journal-id-type="pmc-domain-id">822</journal-id><journal-id journal-id-type="pmc-domain">acssd</journal-id><journal-id journal-id-type="publisher-id">jm</journal-id><journal-title-group><journal-title>Journal of Medicinal Chemistry</journal-title></journal-title-group><issn pub-type="ppub">0022-2623</issn><issn pub-type="epub">1520-4804</issn><self-uri>pubs.acs.org/jmc</self-uri><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>ACS AuthorChoice</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12406194</article-id><article-id pub-id-type="pmcid-ver">PMC12406194.1</article-id><article-id pub-id-type="pmcaid">12406194</article-id><article-id pub-id-type="pmcaiid">12406194</article-id><article-id pub-id-type="pmid">40763221</article-id><article-id pub-id-type="doi">10.1021/acs.jmedchem.5c01641</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Perspective</subject></subj-group></article-categories><title-group><article-title>A Data-Driven Perspective
on Bioisostere Evaluation:
Mapping the Benzene Bioisostere Landscape with BioSTAR</article-title></title-group><contrib-group id="CONTRIB-GROUP-d14e22-autogenerated"><contrib id="ath1" contrib-type="author" corresp="yes"><contrib-id contrib-id-type="paragon-plus" authenticated="true">7367446</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-2465-3949</contrib-id><name name-style="western"><surname>Hern&#225;ndez-Llad&#243;</surname><given-names initials="P">Pol</given-names></name><xref rid="cor1" ref-type="corresp"/><xref rid="aff1" ref-type="aff"/></contrib><contrib id="ath2" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">250675</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-8857-1515</contrib-id><name name-style="western"><surname>Meanwell</surname><given-names initials="NA">Nicholas A.</given-names></name><xref rid="aff3" ref-type="aff"/><xref rid="aff4" ref-type="aff"/><xref rid="aff5" ref-type="aff"/><xref rid="aff6" ref-type="aff"/></contrib><contrib id="ath3" contrib-type="author" corresp="yes"><contrib-id contrib-id-type="paragon-plus" authenticated="true">971391</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-3610-9369</contrib-id><name name-style="western"><surname>Russell</surname><given-names initials="AJ">Angela J.</given-names></name><xref rid="cor2" ref-type="corresp"/><xref rid="aff1" ref-type="aff"/><xref rid="aff2" ref-type="aff"/></contrib><aff id="aff1">
<label>&#8224;</label>
<institution content-type="dept">Department
of Chemistry, Chemistry Research Laboratory</institution>, <institution-wrap><institution-id institution-id-type="Ringgold" specific-use="source:pplus">6396</institution-id><institution>University of Oxford</institution></institution-wrap>, <addr-line>Mansfield Road</addr-line>, <city>Oxford</city>
<postal-code>OX1 3TA</postal-code>, <country country="GB">U.K.</country>
</aff><aff id="aff2">
<label>&#8225;</label>
<institution content-type="dept">Department
of Pharmacology</institution>, <institution>University of Oxford</institution>, <addr-line>Mansfield Road</addr-line>, <city>Oxford</city>
<postal-code>OX1 3QT</postal-code>, <country country="GB">U.K.</country>
</aff><aff id="aff3">
<label>&#167;</label>
<institution-wrap><institution-id institution-id-type="Ringgold" specific-use="source:pplus">480639</institution-id><institution>The
Baruch S. Blumberg Institute</institution></institution-wrap>, <addr-line>3805 Old Easton Road</addr-line>, <city>Doylestown</city>, <state>Pennsylvania</state>
<postal-code>18902</postal-code>, <country country="US">United States</country>
</aff><aff id="aff4">
<label>&#8741;</label>
<institution content-type="dept">The
School of Pharmacy</institution>, <institution>The University of Michigan</institution>, <city>Ann Arbor</city>, <state>Michigan</state>
<postal-code>48109</postal-code>, <country country="US">United States</country>
</aff><aff id="aff5">
<label>&#8869;</label>
<institution content-type="dept">The
Ernest Mario School of Pharmacy</institution>, <institution>Rutgers
University</institution>, <city>Piscataway</city>, <state>New Jersey</state>
<postal-code>08854</postal-code>, <country country="US">United States</country>
</aff><aff id="aff6">
<label>#</label>
<institution>NuArq MedChem
Consulting LLC</institution>, <city>Yardley</city>, <state>Pennsylvania</state>
<postal-code>19067</postal-code>, <country country="US">United States</country>
</aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>Email; <email>pol.hernandezllado@chem.ox.ac.uk</email>.</corresp><corresp id="cor2"><label>*</label>Email; <email>angela.russell@chem.ox.ac.uk</email>.</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>05</day><month>8</month><year>2025</year></pub-date><pub-date date-type="collection" publication-format="electronic"><day>28</day><month>8</month><year>2025</year></pub-date><volume>68</volume><issue>16</issue><issue-id pub-id-type="pmc-issue-id">496131</issue-id><fpage>16921</fpage><lpage>16939</lpage><history><date date-type="received"><day>16</day><month>6</month><year>2025</year></date><date date-type="accepted"><day>28</day><month>7</month><year>2025</year></date><date date-type="rev-recd"><day>24</day><month>7</month><year>2025</year></date><date date-type="online"><day>05</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>03</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 00:25:59.930"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Authors. Published by American Chemical Society</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>The Authors</copyright-holder><ali:free_to_read content-type="AuthorChoicev2" start_date="2025-08-05"/><license><ali:license_ref specific-use="textmining" content-type="ccbylicense" start_date="2025-08-05">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is licensed under CC-BY 4.0</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="jm5c01641.pdf"/><abstract><p>The bioisostere landscape
is continually expanding, with new scaffolds
emerging as alternatives in drug design. Increasingly, medicinal chemists
face the challenge of selecting and prioritising these bioisosteres,
often relying on personal experience and anecdotal evidence. In this
Perspective, we lay out a data-driven approach to analyze the bioisostere
landscape, using benzene bioisosteres as a representative example,
and quantitatively compare replacements based on their impact on bioactivity,
solubility, and metabolic stability. To support the findings of the
analysis, we highlight recent and particularly elegant examples of
benzene bioisostere applications while identifying areas where further
development could significantly benefit the community. By providing
this Perspective and associated data-mining workflow (BioSTAR), we
aim to support more informed decision-making in bioisosteric replacement
selection in drug design and inspire future innovations in bioisostere
design.</p></abstract><abstract abstract-type="graphical"><graphic position="float" orientation="portrait" xlink:href="jm5c01641_0027.jpg"/></abstract><abstract abstract-type="toc-graphic"><graphic id="tgr1" position="float" orientation="portrait" xlink:href="jm5c01641_0025.jpg"/></abstract><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>document-id-old-9</meta-name><meta-value>jm5c01641</meta-value></custom-meta><custom-meta><meta-name>document-id-new-14</meta-name><meta-value>jm5c01641</meta-value></custom-meta><custom-meta><meta-name>production-flag-MathML-config-version</meta-name><meta-value>3</meta-value></custom-meta><custom-meta><meta-name>production-flag-journal-citation-display-style</meta-name><meta-value>acs-titles</meta-value></custom-meta><custom-meta><meta-name>production-flag-journal-date-display-style</meta-name><meta-value>dates-used-rcd-rvd-acc</meta-value></custom-meta><custom-meta><meta-name>production-flag-si-avail</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>document-id-alt-64</meta-name><meta-value>fec49733ee7cb3a95baa14ece7e8b72977621d9978bb14262a1d41a490e5205c</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1"><title>Significance</title><p>
<list list-type="bullet"><list-item><p>The expanding bioisostere landscape
poses a central
challenge in medicinal chemistry: how to systematically compare and
prioritize scaffolds.</p></list-item><list-item><p>This Perspective
advocates for a data-driven approach
and provides a data-mining workflow (BioSTAR) to evaluate bioisosteric
replacements.</p></list-item><list-item><p>Using benzene bioisosteres
as a case study, we assess
their impact on bioactivity, solubility, and metabolic stability.</p></list-item><list-item><p>The workflow serves as a practical tool
for medicinal
chemists and a foundation for collaborative, data-driven progress
in molecular design.</p></list-item></list>
</p></sec><sec id="sec2"><title>Introduction</title><p>Over
the past two decades, particularly following the landmark
publication of the &#8220;Escape from Flatland&#8221; paper by Lovering
et al.,<xref rid="ref1" ref-type="bibr"/> the medicinal chemistry community
has sought to increase the three-dimensionality of lead compounds.
This is because a higher Fsp<sup>3</sup> correlates with better progression
from discovery through preclinical and clinical development and to
the market, as well as improved physicochemical and absorption, distribution,
metabolism and elimination (ADME) properties.<xref rid="ref1" ref-type="bibr"/> Fsp<sup>3</sup>, as well as number of chiral centers, is also linked
to decreased promiscuity, and thus may help address toxicity, a leading
cause of attrition in the clinic.<xref rid="ref2" ref-type="bibr"/> More
recent analyses suggest that the utility of Fsp<sup>3</sup> as a predictive
metric for clinical trial progression may have been overstated, as
the trends observed in 2009 have not persisted.<xref rid="ref3" ref-type="bibr"/> Notwithstanding, other metrics related to compound three-dimensionality
also correlate with improved developability. For example, Ritchie
and Macdonald elegantly showed that an increased aromatic ring count
correlates with lower solubility, higher serum albumin binding, and
higher clogP, leading to overall poorer developability.<xref rid="ref4" ref-type="bibr"/>These results align with Leeson&#8217;s findings,
which highlight reduced carboaromaticity as a key feature distinguishing
approved drugs from other molecules acting on the same target.<xref rid="ref5" ref-type="bibr"/> In line with these analyses, a common strategy
in medicinal chemistry to improve molecular properties has been the
use of arene bioisosteres to replace sp<sup>2</sup>-rich aromatic
rings with sp<sup>3</sup>-rich alternative motifs. This has led to
the development and rediscovery of scaffolds designed to serve as
arene bioisosteres.</p><p>The growing interest in this area is evident
from the surging number
of publications referencing the term &#8243;bioisostere&#8243; since
2009. Caged hydrocarbons have received particular attention, as exemplified
by bicyclo[1.1.1]&#173;pentanes (BCPs),<named-content content-type="bibref-group">
<xref rid="ref6" ref-type="bibr"/>&#8722;<xref rid="ref7" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref8" ref-type="bibr"/>
</named-content> bicyclo[2.1.1]&#173;hexanes
(BCHs),<named-content content-type="bibref-group">
<xref rid="ref9" ref-type="bibr"/>&#8722;<xref rid="ref10" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref11" ref-type="bibr"/>
</named-content> bicyclo[3.1.1]&#173;heptanes (BCHeps),<named-content content-type="bibref-group">
<xref rid="ref12" ref-type="bibr"/>,<xref rid="ref13" ref-type="bibr"/>
</named-content> cubanes,<named-content content-type="bibref-group">
<xref rid="ref14" ref-type="bibr"/>&#8722;<xref rid="ref15" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref16" ref-type="bibr"/>
</named-content> and other, less common scaffolds such as cuneanes<named-content content-type="bibref-group">
<xref rid="ref17" ref-type="bibr"/>&#8722;<xref rid="ref18" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref19" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref20" ref-type="bibr"/>
</named-content> and stellanes.<xref rid="ref21" ref-type="bibr"/> Their popularity can
be attributed to their well-defined exit vectors, which can closely
mimic those of arenes, along with their high sp<sup>3</sup> character
and rigidity, which minimizes entropic penalties upon target binding.
Several excellent reviews have examined the benzene bioisostere field.<named-content content-type="bibref-group">
<xref rid="ref22" ref-type="bibr"/>&#8722;<xref rid="ref23" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref24" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref25" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref26" ref-type="bibr"/>
</named-content>
</p><p>Medicinal chemists are increasingly incorporating these scaffolds
into their compound designs. By replacing a benzene ring with a potentially
bioisosteric group, the designer aims to improve a molecule&#8217;s
overall profile, for example, increasing its solubility or metabolic
stability, while preserving bioactivity. Nonetheless, the impact of
such replacements on bioactivity and other molecular properties is
often context-dependent, making their impact challenging to predict.
Compounding this, the growing number of benzene bioisosteres in the
literature raises a new challenge: selecting which isosteric scaffolds
to prioritise for synthesis.</p><p>In this perspective, we have employed
a data-driven approach to
evaluate and compare benzene bioisosteres in order to address these
challenges. To achieve this, we developed a data-mining workflow,
which we have made publicly available and offers a versatile, user-friendly
framework for evaluating other bioisosteric replacements.</p></sec><sec id="sec3"><title>Bioisosteres:
Definition and Evaluation</title><sec id="sec3.1"><title>Isostere and Bioisostere Definitions</title><p>The concept of
isosterism was first introduced by Irving Langmuir in 1919,<xref rid="ref27" ref-type="bibr"/> building on earlier work by James Moir in 1909.<xref rid="ref28" ref-type="bibr"/> Initially, the definition was restricted to
pairs of molecules or atomic groups with similar electron configurations,
such as N<sub>2</sub>O and CO<sub>2</sub>. In 1932, Erlenmeyer broadened
this definition to include &#8243;<italic toggle="yes">elements, molecules, or
ions in which the peripheral layers of electrons may be considered
identical</italic>.&#8243;<xref rid="ref29" ref-type="bibr"/>
</p><p>The
term bioisosterism was introduced by Friedman in 1950, who defined
bioisosteres as structural moieties that &#8243;<italic toggle="yes">fit the broadest
definition of isosteres and exhibit the same type of biological activity</italic>.&#8243;<xref rid="ref30" ref-type="bibr"/> In this seminal work, Friedman
emphasized that while isosterism was a necessary condition for bioisosterism,
it was not sufficient due to the complexity of biological systems
and the characteristics of molecular recognition. The publication
also presented an early example of matched molecular pair (MMP) analysis.</p><p>Thornber later expanded Friedman&#8217;s definition to include
nonclassical bioisosteres, describing bioisosteres as &#8243;groups
or molecules with chemical and physical similarities that result in
broadly similar biological properties.&#8243;<xref rid="ref31" ref-type="bibr"/> This expanded definition is widely accepted today.</p></sec><sec id="sec3.2"><title>Data-Mining
Approaches for Bioisostere Evaluation</title><p>Potential
bioisosteric replacements can be evaluated through data-mining methods
that identify MMPs in the literature and analyze the effects of the
replacements on properties such as bioactivity, solubility, or metabolic
stability.<named-content content-type="bibref-group">
<xref rid="ref32" ref-type="bibr"/>,<xref rid="ref33" ref-type="bibr"/>
</named-content>
</p><p>EMIL, the first database
of this kind manually curated by Fujita and colleagues in the early
1990s, collated examples of MMPs and summarized the effect the molecular
scaffold had on activity, toxicity, metabolic stability and other
parameters.<xref rid="ref34" ref-type="bibr"/> BIOSTER, developed at the
same time by Ujv&#225;ry, is a similar database containing over
28,000 bioisosteric transformations manually curated from the literature,
although patents are excluded.<xref rid="ref35" ref-type="bibr"/>
</p><p>
<italic toggle="yes">In silico</italic> methods were later developed to perform
comprehensive analyses of the literature. These employ fragmentation
and clustering algorithms to mine bioactivity databases and identify
bioisosteric replacements. Sheridan and Miller&#8217;s maximum common
substructure (MCS) algorithm,<xref rid="ref36" ref-type="bibr"/> and Hussain
and Rea&#8217;s fragmentation and indexing (F+I) algorithm are common
methods employed to achieve this.<xref rid="ref37" ref-type="bibr"/>
</p><p>An example of an <italic toggle="yes">in silico</italic>-curated bioisostere
database is SwissBioisostere, a web-based, freely accessible resource
that enables users to search for bioisosteric replacements of specific
scaffolds and provides a summary of their effects on activity, Log<italic toggle="yes">P</italic>, topological polar surface area (tPSA), and molecular
weight.<named-content content-type="bibref-group">
<xref rid="ref38" ref-type="bibr"/>,<xref rid="ref39" ref-type="bibr"/>
</named-content> SwissBioisostere uses data from the ChEMBL
database, processed through a fragmentation and indexing algorithm,
and is a powerful, user-friendly tool; however, it was last updated
in 2021 (ChEMBL version: 28) and its algorithm is not open-access.</p><p>A complementary, <italic toggle="yes">in silico</italic>-curated tool, the Ring
Replacement Recommender, was developed by Ertl et al.<xref rid="ref40" ref-type="bibr"/> This web-based resource suggests alternative ring systems
for the 245 most frequently used rings, prioritising those associated
with at least a 2-fold increase in potency. The recommendations are
derived from MMP analysis of data from ChEMBL (version 29).</p><p>Data-mining approaches have also been successfully applied to protein&#8211;ligand
complexes. These are hybrid methods that compare interaction pattern
graphs of published crystal structures and identify alternative molecular
scaffolds capable of achieving similar interactions with the protein.<xref rid="ref41" ref-type="bibr"/> sc-PDB-frag is an online tool that identifies
bioisosteric replacements for specific fragments bound to a protein
through mining of the protein data bank (PDB).<xref rid="ref42" ref-type="bibr"/> The scarcity of cocrystal structures available limits the
application of these methods to well-precedented scaffolds.</p></sec></sec><sec id="sec4"><title>An
Open-Source Data-Mining Workflow for Bioisostere Evaluation</title><p>To evaluate and compare potential benzene bioisosteres, we quantified
the overall effect of these molecular replacements on the key properties
of bioactivity, solubility, metabolic stability, and membrane permeability.
This analysis was conducted using an open-access data-mining workflow,
which we termed BioSTAR (BioiSosTere Analysis and Ranking).<xref rid="ref200" ref-type="bibr"/> The BioSTAR workflow employs free, open-source
software and can be run on a single benchtop computer by users with
no computational experience. It uses Knime as the data-processing
software and ChEMBL (version 35, released December 2024) as the open-access
database, but it can also be applied to other databases. The output
files are visualized with the open-source program DataWarrior.<xref rid="ref43" ref-type="bibr"/> These characteristics allow others to repeat
the bioisostere evaluation over time and as more data becomes available,
and apply it to any molecular transformation of interest.</p><p>Employing
the BioSTAR workflow we identified MMPs in ChEMBL differing
only by the bioisostere investigated and compared all of their available
data (bioactivity, solubility, clearance and membrane permeability).
Only homogeneous pairs, i.e., pairs of data points obtained from the
same assay in the same publication, were included in the analysis.
This was informed by the studies of Kramer and co-workers who showed
that many fewer data points are required to reach statistical significance
when using homogeneous pairs, when compared to a combination of homogeneous
and heterogeneous pairs.<xref rid="ref44" ref-type="bibr"/> This condition
for homogeneity also allowed a more computationally efficient workflow,
since only structures within the same document were included in the
MMP-searching algorithm.</p><p>The data-mining workflow employed is
summarized below and in <xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig"/>
</xref>:<list list-type="simple"><list-item><label>1.</label><p>Structure
preparation by removal of
salts and stereocenters. The F+I algorithm employed in the workflow
cannot handle defined stereocenters or double bond geometries, which
is an important limitation. Nonetheless, the workflow output can be
later processed to extract this information.</p></list-item><list-item><label>2.</label><p>Substructure search in ChEMBL for the
identification of molecules containing the scaffold of interest.</p></list-item><list-item><label>3.</label><p>Extraction of documents
containing
the scaffold of interest.</p></list-item><list-item><label>4.</label><p>Mining of all structures within the
identified documents.</p></list-item><list-item><label>5.</label><p>Mining of all data associated with
these structures. Only exact values, without qualifiers such as &lt;
or &gt;, were included in the analysis.</p></list-item><list-item><label>6.</label><p>Processing of the resulting structures
with a fragmentation algorithm. The fragmentation algorithm (Hussain
and Rea)<xref rid="ref37" ref-type="bibr"/> was applied for 1 and 2 cuts
for acyclic single bonds to rings, although the selection of alternative
fragmentation patterns is possible to explore other replacements.
Filtering based on the number of heavy atoms in the investigated scaffolds
was applied to streamline processing.</p></list-item><list-item><label>7.</label><p>Filtering for homogeneous pairs. Only
MMPs with molecules originating from the same document and data derived
from the same assay were retained for analysis.</p></list-item><list-item><label>8.</label><p>Calculation of differences in properties.</p></list-item><list-item><label>9.</label><p>Substructure search to
filter results
by transformation.</p></list-item></list>
</p><fig position="float" id="fig1" fig-type="figure" orientation="portrait"><label>1</label><caption><p>Schematic representation
of the BioSTAR workflow and results obtained
when performing search on BCP scaffold. In red, time required to complete
each process.</p></caption><graphic id="gr1" position="float" orientation="portrait" xlink:href="jm5c01641_0001.jpg"/></fig><p>The workflow described above allowed
us to collate all the data
available on ChEMBL for a list of scaffolds of interest. This process
could be performed on a benchtop computer with no need for parallel
processing or extended times. For example, the data-mining required
to evaluate the replacement of a <italic toggle="yes">para</italic>-substituted
benzene ring for a disubstituted BCP was completed in 16 min and 57
s.<xref rid="ref45" ref-type="bibr"/> The BioSTAR workflow was designed
for use by medicinal chemists with no previous computational experience,
requiring as input solely the structure of the scaffold being replaced
and the potential bioisostere investigated.</p></sec><sec id="sec5"><title>Quantitative Evaluation
of Benzene Bioisosteres</title><p>The BioSTAR workflow was used to
evaluate and compare benzene bioisosteres.
This was motivated by the increasing number of scaffolds described
as such, which often leads to challenges in prioritisation of designed
compounds for synthesis.</p><sec id="sec5.1"><title>Summary of the Matched Molecular Pair Analysis</title><p>We initiated
the data-mining analysis by selecting the benzene bioisosteres to
be investigated. The selection was guided by previous reports of bioisosterism
from both the primary literature and review articles, with a focus
on saturated mono- and polycyclic scaffolds.<named-content content-type="bibref-group">
<xref rid="ref22" ref-type="bibr"/>,<xref rid="ref23" ref-type="bibr"/>,<xref rid="ref25" ref-type="bibr"/>,<xref rid="ref26" ref-type="bibr"/>
</named-content> The selected
scaffolds are compiled in <xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig"/>
</xref>. Heteroaromatic ring systems, often used as benzene
bioisosteres, were excluded from this analysis in favor of nonclassical
bioisosteres. Nonetheless, the general applicability of the BioSTAR
workflow allows it to be extended to the analysis of such substitutions.
The role of heteroaromatics as benzene bioisosteres has previously
been reviewed by Ritchie and Macdonald,<xref rid="ref46" ref-type="bibr"/> and Subbaiah and Meanwell.<xref rid="ref23" ref-type="bibr"/>
</p><fig position="float" id="fig2" fig-type="figure" orientation="portrait"><label>2</label><caption><p>Scaffolds investigated
as potential benzene bioisosteres. No homogeneous
MMPs were found in ChEMBL (version 35) for the scaffolds colored red.</p></caption><graphic id="gr2" position="float" orientation="portrait" xlink:href="jm5c01641_0002.jpg"/></fig><p>Using the BioSTAR workflow on the ChEMBL database
(version 35),
we extracted bioactivity data for 21,868 homogeneous MMPs containing
the scaffolds shown in <xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig"/>
</xref>. The molecular replacements with the highest number of homogeneous
pairs were monosubstituted benzene ring to cyclohexane (<italic toggle="yes">N</italic> = 9672), cyclopropane (<italic toggle="yes">N</italic> = 3982), cyclopentane
(<italic toggle="yes">N</italic> = 2551) or cyclobutene (<italic toggle="yes">N</italic> = 1075).
For <italic toggle="yes">para</italic>-substituted benzene rings, replacement by
a 1,4-cyclohexane was the most precedented substitution (<italic toggle="yes">N</italic> = 876), which was also true for <italic toggle="yes">meta</italic>- (1,3-cyclohexane, <italic toggle="yes">N</italic> = 112) and <italic toggle="yes">ortho</italic>-substituted benzenes
(1,2-cyclohexane, <italic toggle="yes">N</italic> = 116). On the other hand, no
MMPs were found containing oxabicyclo[2.2.2]&#173;octane (<bold>13</bold>), azabicyclo[2.2.2]&#173;octane (<bold>14</bold>), oxabicyclo[2.1.1]&#173;hexane
(<bold>23</bold>), BCHep (<bold>24</bold>), cuneane (<bold>28</bold>) or stellane (<bold>29</bold>).</p><p>The available data on physicochemical
and ADME properties in ChEMBL
was considerably more limited. For the bioisosteres investigated,
we obtained a total of 202 solubility, 198 clearance, and 132 permeability
data points. Similar to the bioactivity data, MMPs involving the replacement
of a monosubstituted benzene with a cyclohexane ring were the most
frequently observed across all three properties. At this time, for
many of the investigated scaffolds no data beyond bioactivity was
available.</p><p>A key limitation of this data-driven approach is
the positive bias
introduced by the under-reporting of unsuccessful experiments. This
bias is likely more pronounced for less-precedented scaffolds, thus
requiring cautious interpretation of the results obtained with these
cases. Additionally, the partial coverage of the patent literature
in ChEMBL is another important factor to consider when evaluating
the outcomes of this analysis.</p></sec><sec id="sec5.2"><title>Effects on Bioactivity</title><p>The change in bioactivity resulting
from a molecular transformation defines its bioisosteric nature; consequently,
analyzing this effect is central to evaluating bioisosteres. The results
of the MMP analysis are summarized in <xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>, which illustrates the impact that each
molecular transformation had on bioactivity, solubility, and clearance. <xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref> includes transformations
with 5 or more data points in ChEMBL, but all of the results from
the analysis, including descriptive statistics, can be found in the
Supporting Information (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c01641/suppl_file/jm5c01641_si_001.pdf" ext-link-type="uri">Tables S1&#8211;S4</ext-link>).</p><fig position="float" id="fig3" fig-type="figure" orientation="portrait"><label>3</label><caption><p>Summary of the impact of potentially bioisosteric replacements
on bioactivity, solubility, and clearance (Cl<sub>int</sub>). Mean
values are plotted with error bars representing 95% confidence intervals.
(A) Terminal benzene; (B) para-substituted benzene; (C) meta-substituted
benzene; (D) ortho-substituted benzene. <sup>&#8225;</sup>Indicates
substitutions with nonsignificant context dependency (see Supporting
Information, <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c01641/suppl_file/jm5c01641_si_001.pdf" ext-link-type="uri">Tables S1&#8211;S7</ext-link> for details).</p></caption><graphic id="gr3" position="float" orientation="portrait" xlink:href="jm5c01641_0003.jpg"/></fig><p>A key aspect of bioisosterism is its inherent context
dependency.
Despite its significance, this consideration has not been explicitly
incorporated into the analysis thus far. To evaluate the generality
of the results obtained, we classified each bioactivity data point
according to its biological target, based on ChEMBL&#8217;s protein
classification (level 3). The effect of the molecular replacements
on bioactivity (&#916;&#173;(&#8722;log&#173;(bioactivity))) against each target
family were measured. Subsequently, we employed a Welch&#8217;s one-way
analysis of variance (ANOVA) to assess whether the target family influenced
the observed &#916;&#173;(&#8722;log&#173;(bioactivity)). A statistically significant
result would indicate that the effect of the molecular replacement
depended on the context of the target family, underscoring the context-dependent
nature of bioisosterism. Conversely, a nonsignificant result would
suggest that the target family did not have a significant impact on
the observed effect, implying that the bioisostere can be considered
more general in its applicability. This approach therefore allowed
the assessment of the context-dependency of the investigated bioisosteric
replacements. The transformations that showed no statistically significant
context dependency are highlighted in <xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>. Detailed results of this analysis are included
in the Supporting Information (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c01641/suppl_file/jm5c01641_si_001.pdf" ext-link-type="uri">Tables S1&#8211;S4</ext-link>).</p><p>Among the scaffolds investigated as monosubstituted benzene
bioisosteres,
cyclopentane, BCP, cyclopropane, and cyclohexane showed the smallest
effect on bioactivity (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>A, rows 9&#8211;12). For cyclohexane, this was in line with
Gunaydin and Bartberger&#8217;s analysis, which showed that 36&#8211;45%
of terminal phenyl to cyclohexyl substitutions lead to &#916;pIC<sub>50</sub> &#8804; 0.3 (&#8804;2-fold change).<xref rid="ref47" ref-type="bibr"/> In our analysis, this condition was true for 39% of the
pairs adjudicated. Nonetheless, the bioisosteric nature of cyclohexane,
cyclopentane, and cyclopropane was strongly context dependent, with
effects on bioactivity varying across target families. A more general
replacement based on our analysis, with similarly small effect on
bioactivity, was 1-cyclohexene (row 13). Both bicyclo[2.2.2]&#173;octane
(BCO) and cubane showed significantly positive effects on bioactivity
compared to benzene (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>A, rows 1&#8211;2), which may be due to entropy-driven effects.</p><p>
<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>B shows
the results for <italic toggle="yes">para</italic>-substituted benzene rings. The
replacements leading to smallest changes in bioactivity were 1,4-substituted
cyclohexene, 1,3-substituted cyclobutane, 1,3-substituted cyclopentane,
and 1,4-substituted cyclohexane (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>B, rows 4&#8211;7). Among these, 1,4-substituted
cyclohexene and 1,3-substituted cyclopentane showed nonsignificant
effects of context, and thus were the most general replacements. The
context-dependency of the replacement of a <italic toggle="yes">para</italic>-substituted
benzene by 1,2-substituted cyclopentane could not be assessed due
to the limited data available (2 target families). Based on our analysis,
a more generally bioisosteric replacement of <italic toggle="yes">para</italic>-substituted benzene rings is the 1,3-substituted BCP moiety (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>B, row 8).</p><p>The impact of potentially bioisosteric replacements for <italic toggle="yes">meta</italic>- and <italic toggle="yes">ortho</italic>-substituted benzene rings
are summarized in <xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>C,D. In both cases, 1,2- and 1,3-disubstituted monocycloalkanes
emerged as the most frequently reported replacements.</p><p>For a <italic toggle="yes">meta</italic>-substituted benzene, 1,3-substituted
cyclohexane and 1,3-substituted cyclobutane exhibited the smallest
effects on bioactivity (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>C, rows 4&#8211;5), with context having no significant impact
on the effects derived from the former. Although less precedented,
the use of 1,3-substituted cyclopentane as a <italic toggle="yes">meta</italic>-substituted benzene bioisostere was supported by our analysis, which
showed that this replacement led to no significant impact on bioactivity
across target families (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>C, row 6).</p><p>For <italic toggle="yes">ortho</italic>-substituted benzene,
1,2-substituted
cyclohexane and 1,2-substituted cyclohexene resulted in the smallest
changes in bioactivity, although the observed effects were strongly
context-dependent (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>D, rows 5&#8211;6).</p><p>These findings underscore the scarcity
of effective bioisosteric
replacements for <italic toggle="yes">meta</italic>- and <italic toggle="yes">ortho</italic>-substituted benzene rings. Recent studies have highlighted the potential
of 2-oxabicyclo[2.1.1]&#173;hexanes,<xref rid="ref48" ref-type="bibr"/> BCHeps,<xref rid="ref13" ref-type="bibr"/> and 1,3-cubanes<xref rid="ref14" ref-type="bibr"/> as <italic toggle="yes">meta</italic>-benzene bioisosteres, and of BCHs<xref rid="ref49" ref-type="bibr"/> as <italic toggle="yes">ortho</italic>-benzene bioisosteres.
Nonetheless, additional data are needed to further validate their
bioisosteric behavior and impact on solubility, clearance, and other
molecular properties. Developing further methods to synthesize appropriately
substituted carbocyclic scaffolds, such as BCHs, BCHeps and cubanes,
and incorporating these into bioactive molecules will be crucial to
address this gap in the literature.</p><p>An important consideration
when interpreting <xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref> is the influence of lipophilicity on the
effect of bioisosteric replacements. Increased lipophilicity often
correlates with enhanced bioactivity, largely due to favorable desolvation
and associated entropic gains during binding.<xref rid="ref50" ref-type="bibr"/> Nonetheless, as noted by Hann, such potency gains may come at the
expense of overall developability, due to poorer physicochemical properties
of structures suffering from &#8220;molecular obesity&#8221;.<xref rid="ref51" ref-type="bibr"/> In this data set, there was no overall correlation
between &#916;log&#173;(bioactivity) and &#916;clogP when aggregating
all bioisosteric replacements, suggesting that lipophilicity is not
the primary driver of the observed bioactivity changes (see Supporting
Information, <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c01641/suppl_file/jm5c01641_si_001.pdf" ext-link-type="uri">Figure S2</ext-link> for details). However,
when focusing on the replacement of <italic toggle="yes">mono</italic>-substituted
benzene, a weak but statistically significant correlation was detected,
indicating that lipophilicity is contributing to the bioactivity changes
observed in this subset of transformations. No significant correlation
between &#916;log&#173;(bioactivity) and &#916;clogP was detected for
the replacement of <italic toggle="yes">para</italic>-, <italic toggle="yes">meta</italic>-,
or <italic toggle="yes">ortho</italic>-substituted benzene.</p><p>The BioSTAR workflow
cannot handle stereocenters, and thus the
aforementioned results did not distinguish between <italic toggle="yes">cis</italic> and <italic toggle="yes">trans</italic> isomers of disubstituted rings. The workflow
outputs could, however, be analyzed based on the relative configuration
of stereocenters (see Supporting Information, <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c01641/suppl_file/jm5c01641_si_001.pdf" ext-link-type="uri">Figure S1</ext-link> for details). The only replacement where the impact
on bioactivity was significantly different between stereoisomers was
the replacement of a <italic toggle="yes">para</italic>-substituted benzene ring
with a 1,4-substituted cyclohexane. In this instance, <italic toggle="yes">trans</italic>-1,4-substituted cyclohexane was a better bioisostere than its <italic toggle="yes">cis</italic> stereoisomer, leading to a smaller change in bioactivity
(<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig"/>
</xref>). The closer
geometric similarity between the exit vectors of the <italic toggle="yes">trans</italic> isomer and the <italic toggle="yes">para</italic>-substituted benzene may account
for this difference in behavior (<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig"/>
</xref>).</p><fig position="float" id="fig4" fig-type="figure" orientation="portrait"><label>4</label><caption><p>Effect of relative stereochemistry on 1,4-cyclohexanes
as para-substituted
benzene bioisosteres. Data are presented as mean &#177; 95% confidence
interval. Welch&#8217;s <italic toggle="yes">t</italic> test was used to assess
whether the mean bioactivity changes differed significantly between
cis and trans isomers, accounting for unequal variances. Significance
is indicated as follows: <italic toggle="yes">p</italic> &lt; 0.05 (*), <italic toggle="yes">p</italic> &lt; 0.01 (**). Summary of the exit vector geometries
for 1,4-dimethylbenzene, trans- and cis-1,4-dimethylcyclohexane.</p></caption><graphic id="gr4" position="float" orientation="portrait" xlink:href="jm5c01641_0004.jpg"/></fig></sec><sec id="sec5.3"><title>Effects on Solubility</title><p>The bioisosteric
replacement
of benzene rings is often used in compound design to improve the physicochemical
properties of the molecules, including their solubility. The BioSTAR
workflow has allowed a comprehensive analysis of the literature to
evaluate whether these replacements have a significant impact on solubility,
as well as ADME properties such as metabolic stability and cell permeability.</p><p>Solubility measurements are highly condition-dependent; however,
the data filtering process in the BioSTAR workflow, restricted to
homogeneous pairs (i.e., data points from the same publication measured
under identical conditions), mitigates this source of variability.
The results of this solubility analysis, which includes kinetic and
thermodynamic measures, are also included in <xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref> (see Supporting Information, <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c01641/suppl_file/jm5c01641_si_001.pdf" ext-link-type="uri">Table S5</ext-link> for details). Significant increases
in solubility were observed when a monosubstituted benzene was replaced
with a cyclopropyl, an <italic toggle="yes">N</italic>-methyl piperazine, and a
4-tetrahydropyran (4-THP) ring (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>A, rows 11, 15, 17). These improvements were likely
due to reduced hydrophobicity and/or disrupted crystal packing.<xref rid="ref52" ref-type="bibr"/> Indeed, a statistically significant correlation
was detected between &#916;log&#173;(solubility) and &#916;clogP, linking
increases in solubility to decreased clogP (see Supporting Information, <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c01641/suppl_file/jm5c01641_si_001.pdf" ext-link-type="uri">Figure S2</ext-link> for details). Substitution of a phenyl
ring by piperazine and 3-THP heterocycles also resulted in enhanced
solubility, albeit not to a statistically significant extent (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>A, rows 18&#8211;19).
The replacement of a phenyl group with other hydrophobic moieties,
such as adamantyl, cyclobutyl, cyclopentyl, and cyclohexyl resulted
in no substantial changes in solubility, as is evident from the data
presented in <xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>A, rows 7&#8211;9 and 12.</p><p>Our analysis confirmed that the
use of 1,4-substituted cyclohexane
and BCP as <italic toggle="yes">para</italic>-substituted benzene bioisosteres
leads to a statistically significant increase in solubility (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>B, rows 7&#8211;8).
Notably, the incorporation of BCP produced the largest effect in the
data set, resulting in a mean solubility increase of over an order
of magnitude. These findings were in line with earlier reports in
the literature.<named-content content-type="bibref-group">
<xref rid="ref8" ref-type="bibr"/>,<xref rid="ref53" ref-type="bibr"/>
</named-content>
</p><p>Solubility data in ChEMBL
for <italic toggle="yes">meta</italic>- and <italic toggle="yes">ortho</italic>-substituted
benzene derivatives are limited. Nevertheless,
significant solubility enhancements were observed when replacing a <italic toggle="yes">meta</italic>-substituted benzene with a 1,3-substituted cyclopentane
(<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>C, row 6)
and an <italic toggle="yes">ortho</italic>- substituted benzene with a 1,2-substituted
cyclohexane (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>D, row 6).</p></sec><sec id="sec5.4"><title>Effects on Metabolic Stability</title><p>Benzene
rings are susceptible
to oxidative metabolism to give phenols and dihydroxybenzenes, with
the latter subject to further oxidation to afford quinone-based species
that can form glutathione adducts.<xref rid="ref54" ref-type="bibr"/> In
order to avoid this, and to improve the metabolic stability of compounds,
practitioners often replace these aromatic rings with saturated bioisosteres.
We employed the BioSTAR workflow to evaluate the effect these replacements
had on metabolic stability across the ChEMBL database. Homogenous
pairs of both hepatocyte and liver microsome clearance data were pooled,
as well as <italic toggle="yes">in vivo</italic> measures of clearance. Despite
these broad inclusion criteria, the clearance data available are rather
scarce, which limited the number of replacements that could be evaluated.
The results of this analysis are summarized in <xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref> (see Supporting Information, <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c01641/suppl_file/jm5c01641_si_001.pdf" ext-link-type="uri">Table S6</ext-link> for details).</p><p>For monosubstituted
benzene rings, the only replacement that led to a statistically significant
reduction in clearance was the substitution of a phenyl group with
a 4-THP heterocycle (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>A, row 17). This effect was regioisomer-dependent, since replacement
by a 3-THP had no impact on clearance (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>A, row 19). Further examples are, however,
required to confirm this difference in behavior. On the other hand,
the use of cyclohexyl as a phenyl bioisostere had a small but detrimental
effect on metabolic stability (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>A, row 12).</p><p>The <italic toggle="yes">para</italic>-substituted
benzene bioisosteres that
could be assessed showed no significant impact on metabolic stability
(<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>B, rows 5,
7, 10). Nonetheless, the number of examples reported is limited and
this conclusion is thus preliminary. Conversely, the replacement of
a <italic toggle="yes">meta</italic>-substituted benzene with a 1,3-disubstituted
cyclohexane led to a decrease in clearance (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>C, row 4) that is supportive of its incorporation
when the objective is to increase the metabolic stability of lead
compounds.</p><p>The next sections highlight recent, as well as particularly
notable
applications of benzene bioisosteres in drug design. These specific
examples complement the general results of the data-mining analysis
and showcase the utility of benzene bioisosteres in multiparameter
optimization during drug optimization.</p></sec><sec id="sec5.5"><title>Replacement of Terminal
Benzene Rings</title><p>Among the scaffolds
investigated, there were 23 different replacements for terminal benzene
rings with five or more examples in ChEMBL (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>A). Minimal effects on bioactivity were observed
when using small carbocycles such as cyclopropane, cyclopentane, cyclohexane,
as well as BCP as phenyl bioisosteres.</p><p>An example of the use
of a cyclohexane as a phenyl bioisostere is demonstrated by Kitamura
et al. in their development of noncovalent SARS-CoV-2 M<sup>pro</sup> inhibitors.<xref rid="ref55" ref-type="bibr"/> Their design was informed
by the X-ray cocrystal structure of the protease bound to ML188 (<bold>30</bold>), which supported the addition of lipophilic groups to
fill the S2 pocket (<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig"/>
</xref>). Indeed, the addition of either a phenyl or cyclohexyl group
led to similar improvements in potency, showing the bioisosteric nature
of these substituents. Nonetheless, the cyclohexane-based inhibitor <bold>32</bold> was cytotoxic and thus <bold>31</bold> was selected for
further development. The proposed binding of the modified inhibitors
was later confirmed through X-ray crystallography of compound <bold>30</bold> bound to SARS-CoV-2 M<sup>pro</sup> (PDB: 3 V3M), which
showed the phenyl group partaking in favorable hydrophobic interactions.</p><fig position="float" id="fig5" fig-type="figure" orientation="portrait"><label>5</label><caption><p>Schematic
representation of the interactions between ML188 (<bold>30</bold>)
and M<sup>pro</sup> and impact on M<sup>pro</sup> inhibition
and cytotoxicity of the replacement of a phenyl substituent by a cyclohexyl
ring.<xref rid="ref55" ref-type="bibr"/>
</p></caption><graphic id="gr5" position="float" orientation="portrait" xlink:href="jm5c01641_0005.jpg"/></fig><p>The effect of the replacement of a phenyl by a cyclohexyl ring
on bioactivity is, nonetheless, context dependent. This is illustrated
in <xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig"/>
</xref>, which
depicts the impact this substitution has on bioactivity across common
target families (kinases, proteases, and family A GPCRs). The data
show how proteases tend to tolerate this kind of substitution, as
exemplified by SARS-CoV-2 M<sup>pro</sup> cysteine protease inhibitors
depicted in <xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig"/>
</xref>, while in protein kinases this replacement has a significantly deleterious
impact on bioactivity.</p><fig position="float" id="fig6" fig-type="figure" orientation="portrait"><label>6</label><caption><p>Impact of the substitution of a phenyl ring with a cyclohexane
across target families. Data are presented as mean &#177; 95% confidence
interval. Statistical significance was determined using one-way ANOVA
followed by Dunnett&#8217;s multiple comparisons test. Significance
is indicated as follows: <italic toggle="yes">p</italic> &lt; 0.05 (*), <italic toggle="yes">p</italic> &lt; 0.01 (**), <italic toggle="yes">p</italic> &lt; 0.001 (***), <italic toggle="yes">p</italic> &lt; 0.0001 (****).</p></caption><graphic id="gr6" position="float" orientation="portrait" xlink:href="jm5c01641_0006.jpg"/></fig><p>The common negative impact of cyclohexane as a phenyl bioisostere
in the context of protein kinase inhibition was exemplified by Pollard
and colleagues at Vertex during their development of ataxia telangiectasia
mutated and Rad3 related (ATR) protein kinase inhibitors (<xref rid="fig7" ref-type="fig">Figure <xref rid="fig7" ref-type="fig"/>
</xref>).<xref rid="ref56" ref-type="bibr"/> During their lead-optimization efforts, the authors sought
to replace the anilide moiety in <bold>33</bold> with a bioisostere
in order to avoid the formation of potentially toxic anilines <italic toggle="yes">in vivo</italic>. The replacement of the anilide with a cyclohexyl
amide (<bold>34</bold>), nonetheless, resulted in a significant reduction
in potency. A clash with the gatekeeper Tyr2365 residue may subtend
this difference in bioactivity.</p><fig position="float" id="fig7" fig-type="figure" orientation="portrait"><label>7</label><caption><p>Effect of the replacement of a phenyl
group with a cyclohexane
on ATR inhibition.<xref rid="ref56" ref-type="bibr"/>
</p></caption><graphic id="gr7" position="float" orientation="portrait" xlink:href="jm5c01641_0007.jpg"/></fig><p>The replacement of a benzene ring by small aliphatic rings can
lead to increased solubility, often due to reduced aromatic stacking
in the solid state.<xref rid="ref57" ref-type="bibr"/> This effect was most
significant in our data-mining analysis for cyclopropane, as exemplified
by Tear and co-workers in their optimization of small molecules for
the treatment of human African trypanosomiasis (<xref rid="fig8" ref-type="fig">Figure <xref rid="fig8" ref-type="fig"/>
</xref>).<xref rid="ref58" ref-type="bibr"/> This transformation
led to a small reduction in the pEC<sub>50</sub> value but resulted
in much improved solubility and a lower Log<italic toggle="yes">D</italic>. Opposing
effects on metabolic stability were also observed that were species-dependent.</p><fig position="float" id="fig8" fig-type="figure" orientation="portrait"><label>8</label><caption><p>Impact
of the replacement of a phenyl ring by a cyclopropyl group
on T. brucei inhibitory potency, solubility, Log<italic toggle="yes">D</italic>, and clearance in rat hepatocytes and human microsomes.<xref rid="ref58" ref-type="bibr"/>
</p></caption><graphic id="gr8" position="float" orientation="portrait" xlink:href="jm5c01641_0008.jpg"/></fig><p>Partially saturated carbocycles
may sometimes offer advantages
as phenyl bioisosteres. This was showcased by Konteatis et al. in
the discovery of AG-270, an oral methionine adenosyltransferase 2A
(MAT2A) inhibitor for the treatment of tumors with homozygous methylthioadenosine
phosphorylase (MTAP) deletion (<xref rid="fig9" ref-type="fig">Figure <xref rid="fig9" ref-type="fig"/>
</xref>).<xref rid="ref59" ref-type="bibr"/> Among the small rings
explored, 1-substituted cyclohexene led to the biggest improvement
in potency and was ultimately an element of the clinical candidate
AG-270 (<bold>42</bold>).</p><fig position="float" id="fig9" fig-type="figure" orientation="portrait"><label>9</label><caption><p>Impact of the replacement of a monosubstituted
benzene with saturated
and partially saturated carbocycles on MAT2A inhibition. Structure
of the clinical candidate AG-270 (<bold>42</bold>).<xref rid="ref59" ref-type="bibr"/>
</p></caption><graphic id="gr9" position="float" orientation="portrait" xlink:href="jm5c01641_0009.jpg"/></fig><p>Bicyclic scaffolds such as BCPs,
BCHs, BCHeps, and their heteroatom-containing
analogues have recently experienced a resurgence in the literature,
driven by the increase in methodologies for their synthesis and functionalization.<xref rid="ref22" ref-type="bibr"/> So far, examples of their incorporation into
bioactive molecules are scarce and thus their role as benzene bioisosteres
remains tentative. Roecker and colleagues at Merck reported an example
of the use of BCP as phenyl bioisostere as part of their development
of Na<sub>V</sub>1.7 inhibitors (<xref rid="fig10" ref-type="fig">Figure <xref rid="fig10" ref-type="fig"/>
</xref>).<xref rid="ref60" ref-type="bibr"/> To improve
the ADME properties of lead inhibitor <bold>43</bold>, the authors
prepared a number of analogues <bold>44</bold>&#8211;<bold>46</bold> incorporating small alkyl motifs. Replacement of the phenyl moiety
with cyclobutane (<bold>44</bold>) and cyclopropane (<bold>45</bold>) was detrimental to bioactivity, while incorporation of BCP (<bold>46</bold>) resulted in increased inhibitory potency toward Na<sub>v</sub>1.7. This replacement led to similar membrane permeability
and reduced clearance when compared to the prototype <bold>43</bold>. Further development, informed by this series of small aliphatic
replacements, led to the identification of <bold>47</bold> as an inhibitor
with similar inhibitory potency to <bold>43</bold> and <bold>46</bold> but with more balanced properties that showed efficacy in rodent
models of pain.</p><fig position="float" id="fig10" fig-type="figure" orientation="portrait"><label>10</label><caption><p>Impact of the switch from a phenyl to cyclobutane, cyclopropane,
and BCP rings on the inhibition of Na<sub>v</sub>1.7, membrane permeability
and clearance. Structure of the optimized compound <bold>47</bold>.<xref rid="ref60" ref-type="bibr"/>
</p></caption><graphic id="gr10" position="float" orientation="portrait" xlink:href="jm5c01641_0010.jpg"/></fig><p>Larger, hydrophobic groups have also been successfully employed
as phenyl bioisosteres, as demonstrated by Roy et al. in their development
of BCL-X<sub>L</sub> and BCL-2 inhibitors (<xref rid="fig11" ref-type="fig">Figure <xref rid="fig11" ref-type="fig"/>
</xref>).<xref rid="ref61" ref-type="bibr"/> Their crystallography-guided
approach led to the discovery of adamantyl-containing compound <bold>49</bold>, one of the most potent binders for this challenging PPI.
The substitution of a phenyl group with adamantyl was designed to
enhance hydrophobic interactions within a cryptic P5 pocket (highlighted
in green in <xref rid="fig11" ref-type="fig">Figure <xref rid="fig11" ref-type="fig"/>
</xref>), leading to improved potency toward BCL-X<sub>L</sub> and MCL-1.
Compounds <bold>48</bold> and <bold>49</bold> exhibited similar selectivity
profiles against the BCL-2 family proteins, showing low binding to
BCL-W or MCL-1, whereas the adamantyl-containing <bold>49</bold> demonstrated
increased binding affinity for A1. The proposed binding mode of <bold>49</bold> to BCL-X<sub>L</sub> was subsequently confirmed through
X-ray cocrystallography (PDB: <ext-link xlink:href="6UVG" ext-link-type="PDB">6UVG</ext-link>) using the using the analogous but truncated
inhibitor <bold>50</bold> (<xref rid="fig11" ref-type="fig">Figure <xref rid="fig11" ref-type="fig"/>
</xref>).</p><fig position="float" id="fig11" fig-type="figure" orientation="portrait"><label>11</label><caption><p>Effect of phenyl-to-adamantyl substitution on the inhibition
of
BCL-X<sub>L</sub> and related BCL-2 family proteins. X-ray cocrystal
structure of <bold>50</bold> (an analogue of <bold>49</bold>) bound
to BCL-X<sub>L</sub> shown in orange (PDB: <ext-link xlink:href="6UVG" ext-link-type="PDB">6UVG</ext-link>). Hydrophobic regions are highlighted
in green and hydrophilic regions in purple.<xref rid="ref61" ref-type="bibr"/>
</p></caption><graphic id="gr11" position="float" orientation="portrait" xlink:href="jm5c01641_0011.jpg"/></fig><p>Todd and colleagues conducted
a particularly elegant study exploring
larger phenyl bioisosteres in a series of antimalarial agents incorporating
carboranes, scaffolds that have found seldom use by medicinal chemists
(<xref rid="fig12" ref-type="fig">Figure <xref rid="fig12" ref-type="fig"/>
</xref>).<xref rid="ref62" ref-type="bibr"/> In their effort to enhance the solubility and
metabolic stability of a triazolopyrazine series, they replaced the
phenyl ring with cubane, adamantane, and various <italic toggle="yes">closo</italic>-carboranes. Cubane substitution (<bold>53</bold>) preserved antimalarial
activity whereas adamantane (<bold>52</bold>) was less well tolerated.
Remarkably, incorporation of the rarely used 1,2- and 1,7-<italic toggle="yes">closo</italic>-carborane in <bold>54</bold> and <bold>55</bold>,
respectively, led to significantly enhanced activity, while the 1,12-isomer
(<bold>56</bold>) resulted in a reduction in inhibitory potency. The
authors hypothesized that compound potency inversely correlated with
the hydrophobicity of the carborane isomers. However, despite the
promising bioactivity data, analogues <bold>54</bold> and <bold>55</bold> did not produce the desired improvements in solubility and metabolic
stability.</p><fig position="float" id="fig12" fig-type="figure" orientation="portrait"><label>12</label><caption><p>Effect of the replacement of a phenyl ring by adamantane,
cubane,
and carboranes on antimalarial activity, lipophilicity, solubility,
and metabolic stability.<xref rid="ref62" ref-type="bibr"/>
</p></caption><graphic id="gr12" position="float" orientation="portrait" xlink:href="jm5c01641_0012.jpg"/></fig><p>The replacement of phenyl groups with heteroatom-containing
ring
systems such as THP, dioxanes, and piperazines, is less precedented
and on average leads to reduced bioactivity. Thomas and co-workers
replaced the phenyl ring in pyrazolopyrimidine <bold>57</bold> with
a 4-substituted THP (<bold>58</bold>) as part of their development
of treatments for visceral leishmaniasis (<xref rid="fig13" ref-type="fig">Figure <xref rid="fig13" ref-type="fig"/>
</xref>).<xref rid="ref63" ref-type="bibr"/> In this
instance, the change resulted in a relatively small reduction in inhibitory
potency, but was concomitant with a dramatic increase in solubility
and much reduced mouse liver microsomal clearance.</p><fig position="float" id="fig13" fig-type="figure" orientation="portrait"><label>13</label><caption><p>Impact of the substitution
of a phenyl group by 4-THP as part of
the development of treatments against visceral leishmaniasis.<xref rid="ref63" ref-type="bibr"/>
</p></caption><graphic id="gr13" position="float" orientation="portrait" xlink:href="jm5c01641_0013.jpg"/></fig></sec><sec id="sec5.6"><title>Replacement of Para-Substituted
Benzene Rings</title><p>Based
on our data-mining analysis, the replacements for a <italic toggle="yes">para</italic>-substituted benzene with the smallest impact on bioactivity were
1,3-substituted cyclopentane, 1,4-substituted cyclohexane, 1,4-substituted
cyclohexene, and 1,3-substituted cyclobutane (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>). Both 1,4-substituted cyclohexane and a
disubstituted BCP led to significant increases in solubility, while
none of the bioisosteres investigated had a significant impact on
metabolic stability.</p><p>Huang et al. employed 1,4-substituted cyclohexane
as a <italic toggle="yes">para</italic>-substituted benzene bioisostere in their
development of tankyrase (TNKS) inhibitors (<xref rid="fig14" ref-type="fig">Figure <xref rid="fig14" ref-type="fig"/>
</xref>).<xref rid="ref64" ref-type="bibr"/> In line
with our analysis, the <italic toggle="yes">trans</italic> isomer <bold>60</bold> outperformed the <italic toggle="yes">cis</italic> isomer <bold>61</bold> across
all assays. The X-ray cocrystal structures of <bold>59</bold> and <bold>60</bold> complexed with TNKS1 showed good overlap between the <italic toggle="yes">para</italic>- substituted benzene in <bold>59</bold> and the <italic toggle="yes">trans</italic>-1,4-cyclohexane ring in <bold>60</bold>, supporting
the role of this scaffold as bioisosteric.</p><fig position="float" id="fig14" fig-type="figure" orientation="portrait"><label>14</label><caption><p>Impact on TNKS inhibitory
activity and clearance of the replacement
of a para-substituted benzene with cis- and trans-1,4-substituted
cyclohexane. X-ray cocrystal structures of <bold>59</bold> (blue,
PDB: <ext-link xlink:href="4N4T" ext-link-type="PDB">4N4T</ext-link>) and <bold>60</bold> (orange, PDB:4N4 V) with TNKS1. Exit vector analysis of
para- substituted benzene and trans-1,4-substituted cyclohexane (measurements
extracted from the cocrystal structures).<xref rid="ref64" ref-type="bibr"/>
</p></caption><graphic id="gr14" position="float" orientation="portrait" xlink:href="jm5c01641_0014.jpg"/></fig><p>Pu and colleagues demonstrated
the utility of a disubstituted BCP
as a <italic toggle="yes">para-</italic>substituted benzene bioisostere in their
development of indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors (<xref rid="fig15" ref-type="fig">Figure <xref rid="fig15" ref-type="fig"/>
</xref>).<xref rid="ref65" ref-type="bibr"/> In their study, replacing the <italic toggle="yes">para</italic>-substituted
benzene in <bold>62</bold> with a BCP reduced the ALog<italic toggle="yes">P</italic> value by over one logarithmic unit and resulted in a slight reduction
in potency. X-ray cocrystallographic analysis of <bold>62</bold> and <bold>63</bold> bound to IDO1 highlighted the similar angles of the exit
vectors of these scaffolds (<italic toggle="yes">ca</italic>. 180&#176;), and the
shorter distance between them in <bold>63</bold> (2.84 vs 1.93 &#197;).
The shorter distance between hydrogen-bond acceptors may preclude
their effective interaction with both water molecules in IDO1, thus
providing a plausible explanation for the lower inhibitory potency
of BCP-containing analogue <bold>63</bold>. Further optimization of
the BCP-containing series led to the discovery of the potent, orally
available BCP analogue <bold>64</bold>, which was equipotent to the
initial hit <bold>62</bold> but with significantly lower clearance.
The authors attributed this improvement to slower amide hydrolysis
as a result of the incorporation of the BCP core.</p><fig position="float" id="fig15" fig-type="figure" orientation="portrait"><label>15</label><caption><p>Effect of the replacement
of a para-substituted benzene ring with
a disubstituted BCP on IDO1 inhibitory activity, ALog<italic toggle="yes">P</italic>, and Cl<sub>int</sub> and further development toward a candidate
molecule <bold>64</bold>. X-ray cocrystal structures of <bold>62</bold> (blue, PDB: 6 V52) and <bold>63</bold> (orange, PDB: <ext-link xlink:href="6WJY" ext-link-type="PDB">6WJY</ext-link>) with IDO1. Exit
vector analysis of para-substituted benzene and 1,3-BCP (measurements
extracted from the cocrystal structures).<xref rid="ref65" ref-type="bibr"/>
</p></caption><graphic id="gr15" position="float" orientation="portrait" xlink:href="jm5c01641_0015.jpg"/></fig><p>Aguilar and co-workers demonstrated
the utility of a [2.2.2]&#173;BCO
as a bulkier <italic toggle="yes">para</italic>-substituted benzene bioisostere
in the development of murine double minute 2 (MDM2) inhibitors (<xref rid="fig16" ref-type="fig">Figure <xref rid="fig16" ref-type="fig"/>
</xref>).<xref rid="ref66" ref-type="bibr"/> The authors&#8217; extensive SAR study included MMPs in
which the benzene ring of <bold>65</bold> was replaced with various
disubstituted aliphatic scaffolds. Replacement with <italic toggle="yes">trans</italic>-1,4-cyclohexane yielded equipotent compound <bold>66</bold> while
the <italic toggle="yes">cis</italic>-isomer <bold>67</bold>, consistent with our
analysis, exhibited reduced bioactivity across assays. BCP-containing
analogue <bold>68</bold> showed comparable <italic toggle="yes">in vitro</italic> binding affinity but was less potent in the cell-based assay (SJSA-1
xenograft model). Finally, the [2.2.2]&#173;BCO-containing compound <bold>69</bold> maintained similar MDM2 affinity and growth inhibition
to benzoic acid <bold>65</bold>, and had much reduced clearance in
liver microsomal preparations. However, despite its promising pharmacokinetic
profile, compound <bold>69</bold> lacked <italic toggle="yes">in vivo</italic> efficacy,
with no observed tumor regression &#8211; an outcome that the authors
attributed to poor tissue penetration. <italic toggle="yes">N</italic>-Alkylation
of the pyrrolidine ring in compound <bold>69</bold> circumvented this
tissue penetration issue and led to <bold>70</bold>, which showed
100% tumor regression in rat <italic toggle="yes">in vivo</italic> studies. Compound <bold>70</bold> has since advanced into phase II clinical trials for the
treatment of relapsed/refractory T-cell prolymphocytic leukemia (R/R
T-PLL) and non-Hodgkin&#8217;s lymphoma (NHL).<xref rid="ref67" ref-type="bibr"/>
</p><fig position="float" id="fig16" fig-type="figure" orientation="portrait"><label>16</label><caption><p>Impact of replacing a para-substituted benzene ring with
several
disubstituted aliphatic scaffolds on MDM2 affinity, cellular activity,
pharmacokinetic parameters, and in vivo efficacy. Structure of the
resulting clinical candidate <bold>70</bold>.<xref rid="ref66" ref-type="bibr"/>
</p></caption><graphic id="gr16" position="float" orientation="portrait" xlink:href="jm5c01641_0016.jpg"/></fig><p>Partially saturated carbocycles
can also be employed as <italic toggle="yes">para</italic>-substituted benzene
bioisosteres, as showcased by Swidorski
and co-workers in their development of broad-spectrum HIV-1 maturation
inhibitors (<xref rid="fig17" ref-type="fig">Figure <xref rid="fig17" ref-type="fig"/>
</xref>).<named-content content-type="bibref-group">
<xref rid="ref68" ref-type="bibr"/>,<xref rid="ref69" ref-type="bibr"/>
</named-content> Aromatic ring-containing triterpenoid GSK3532795
(<bold>71</bold>) was a candidate that advanced into phase IIb clinical
trials; however, development was halted due to gastrointestinal intolerability
and treatment-emergent resistance. The replacement of the <italic toggle="yes">para</italic>-substituted benzene ring with nonaromatic motifs was
explored as a strategy to ameliorate these issues. Indeed, incorporation
of 1,4-substituted cyclohexene (<bold>72</bold>) or 2,6-substituted
spiro[3.3]&#173;hept-1-ene (<bold>73</bold>) resulted in improved potency
across the HIV-1 mutant strains tested. Further development of cyclohexene <bold>72</bold> led to the discovery of GSK3640254 (<bold>74</bold>), a
second clinical candidate to reach clinical trials, which did not
show treatment-emergent resistance in early clinical studies. In 2024,
the authors disclosed a third clinical candidate incorporating a cyclohexene
ring with further improved antiviral properties and the potential
for once-weekly dosing.<xref rid="ref70" ref-type="bibr"/>
</p><fig position="float" id="fig17" fig-type="figure" orientation="portrait"><label>17</label><caption><p>Effect of the replacement
of a para-substituted benzene with a
1,4-substituted cyclohexene and 2,6-substituted spiro[3.3]&#173;hept-1-ene
in the development of broad spectrum HIV-1 maturation inhibitors.
Structure of the clinical candidate GSK3640254 (<bold>74</bold>).<named-content content-type="bibref-group">
<xref rid="ref68" ref-type="bibr"/>,<xref rid="ref69" ref-type="bibr"/>
</named-content>
</p></caption><graphic id="gr17" position="float" orientation="portrait" xlink:href="jm5c01641_0017.jpg"/></fig><p>1,4-Piperazine generally leads
to a loss in bioactivity when employed
as a <italic toggle="yes">para</italic>-substituted benzene bioisostere, as evidenced
by our MMP analysis (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>). This is often due to its basicity, which results in the
ammonium ion being the predominant species in solution at physiological
pH. Substitution of piperazines with electron withdrawing groups can,
however, lower their p<italic toggle="yes">K</italic>
<sub>a</sub> values and allow
their productive application as <italic toggle="yes">para</italic>-substituted
benzene bioisosteres. Klug and co-workers&#8217; development of small-molecule
treatments for human African trypanosomiasis, which is caused by the
protozoan parasite <italic toggle="yes">Trypanosoma brucei</italic> (<italic toggle="yes">T. brucei</italic>), exemplifies this approach
(<xref rid="fig18" ref-type="fig">Figure <xref rid="fig18" ref-type="fig"/>
</xref>). The authors
replaced the <italic toggle="yes">para</italic>-substituted benzene ring in azaindole <bold>75</bold> with the 1,4-piperazine in <bold>76</bold> which, due to
the methanesulfonyl substituent, is associated with attenuated basicity.
This replacement resulted in a small drop in bioactivity, but was
accompanied by an increase in solubility.<xref rid="ref71" ref-type="bibr"/>
</p><fig position="float" id="fig18" fig-type="figure" orientation="portrait"><label>18</label><caption><p>Impact of the substitution of a para-substituted benzene with a
1,4-piperazine heterocycle in the context on inhibitory activity toward <italic toggle="yes">T. brucei</italic>, clearance, and solubility.<xref rid="ref71" ref-type="bibr"/>
</p></caption><graphic id="gr18" position="float" orientation="portrait" xlink:href="jm5c01641_0018.jpg"/></fig></sec><sec id="sec5.7"><title>Replacement of Meta-Substituted
Benzene Rings</title><p>Our analysis
showed that carbocycles such as 1,3-substituted cyclobutane, 1,3-substituted
cyclopentane, and 1,3-substituted cyclohexane had the smallest impact
on bioactivity when used as <italic toggle="yes">meta-</italic>substituted benzene
bioisosteres. Furthermore, 1,3-substituted cyclopentane led to a significant
increase in solubility.</p><p>An elegant example of the utility of
1,3-cyclohexanes as <italic toggle="yes">meta</italic>-substituted benzene bioisosteres
is their incorporation into SETD2 inhibitors, as demonstrated by Farrow
and co-workers (<xref rid="fig19" ref-type="fig">Figure <xref rid="fig19" ref-type="fig"/>
</xref>).<xref rid="ref72" ref-type="bibr"/> The bis-aniline core in lead
compound <bold>77</bold> led to poor pharmacokinetic properties and
potential metabolism-derived toxicity, prompting the screening of
alternative, saturated scaffolds to address these limitations. Substituting
the problematic <italic toggle="yes">meta-</italic>substituted benzene ring with
a 1,3-substituted cyclohexane yielded the clinical candidate EZM0414
(<bold>78</bold>), which retained similar potency in biochemical assays
while demonstrating enhanced antiproliferative activity and an improved
PK profile. The relative and absolute configuration of the stereocenters
on the cyclohexane ring had a critical impact on bioactivity. X-ray
cocrystal structures of <bold>77</bold>, <bold>78</bold>, and <bold>80</bold> bound to SETD2 revealed that the exit vectors of the <italic toggle="yes">cis</italic>-isomer, bearing the (1<italic toggle="yes">R</italic>,3<italic toggle="yes">S</italic>) configuration, closely mimicked those of the <italic toggle="yes">meta</italic>-substituted benzene ring, providing structural insight into its
functional mimicry (<xref rid="fig19" ref-type="fig">Figure <xref rid="fig19" ref-type="fig"/>
</xref>).</p><fig position="float" id="fig19" fig-type="figure" orientation="portrait"><label>19</label><caption><p>Effect on SETD2 inhibition, cLog<italic toggle="yes">P</italic>, and
clearance
of the replacement of a meta- substituted benzene with a 1,3-substituted
cyclohexane. X-ray cocrystal structures of an analogue of <bold>77</bold> (blue, PDB: <ext-link xlink:href="7LZD" ext-link-type="PDB">7LZD</ext-link>) and EZM0414 (<bold>78</bold>) (orange, PDB: <ext-link xlink:href="7TY2" ext-link-type="PDB">7TY2</ext-link>) with SETD2. Exit
vector analysis of meta-substituted benzene, cis- and trans-1,3-substituted
cyclohexane (measurements extracted from the cocrystal structures
(PDB: <ext-link xlink:href="7LZD" ext-link-type="PDB">7LZD</ext-link>,
7TY2, 7TY3)).<xref rid="ref72" ref-type="bibr"/>
</p></caption><graphic id="gr19" position="float" orientation="portrait" xlink:href="jm5c01641_0019.jpg"/></fig><p>Munck af Rosensch&#246; and colleagues at AstraZeneca showcased
the bioisosteric nature of cyclopropanes in their development of leukotriene
C4 synthase (LTC4S) inhibitors (<xref rid="fig20" ref-type="fig">Figure <xref rid="fig20" ref-type="fig"/>
</xref>).<xref rid="ref73" ref-type="bibr"/> The motivation
behind this replacement strategy was to improve the properties of <bold>82</bold> to allow oral administration. Indeed, substitution of the <italic toggle="yes">meta</italic>-substituted benzene ring with a <italic toggle="yes">trans</italic>-cyclopropane to give carboxylic acid <bold>83</bold> resulted in
the maintenance of inhibitory activity across both the enzyme and
cell-based assays, along with reduced Log<italic toggle="yes">D</italic> and lower
hepatic clearance. Further elaboration of <bold>83</bold> resulted
in the invention of the clinical candidate <bold>84</bold>, which
was progressed into phase I clinical studies.<xref rid="ref74" ref-type="bibr"/>
</p><fig position="float" id="fig20" fig-type="figure" orientation="portrait"><label>20</label><caption><p>Impact of the switch from a meta-substituted a benzene to a cyclopropane
on LTC4S inhibition, Log<italic toggle="yes">D</italic>, and hepatic clearance.
Structure of the clinical candidate <bold>84</bold> resulting from
optimization of <bold>83</bold>.<xref rid="ref73" ref-type="bibr"/>
</p></caption><graphic id="gr20" position="float" orientation="portrait" xlink:href="jm5c01641_0020.jpg"/></fig><p>Scientists at Bristol Myers-Squibb reported the
effects of the
replacement of a <italic toggle="yes">meta-</italic>substituted benzene with a
cyclopentane and a [2.2.1]&#173;BCH as part of their development of interleukin-1
receptor-associated kinase 4 (IRAK4) inhibitors (<xref rid="fig21" ref-type="fig">Figure <xref rid="fig21" ref-type="fig"/>
</xref>).<xref rid="ref75" ref-type="bibr"/> In this context, the three scaffolds led to similarly potent compounds
in the biochemical assays, while in the cell-based assay the compound
bearing a <italic toggle="yes">trans</italic>-1,2-cyclopentane (<bold>87</bold>) was less potent than <bold>85</bold>, <bold>86</bold>, and <bold>88</bold>. The four diastereoisomers of the 1,3-substituted cyclopentane <bold>86</bold> were similarly active, with differences being more pronounced
in the cell-based assay (data not shown).<xref rid="ref75" ref-type="bibr"/>
</p><fig position="float" id="fig21" fig-type="figure" orientation="portrait"><label>21</label><caption><p>Impact of the replacement of a meta-substituted benzene with cyclopentane
and [2.2.1]&#173;BCH on IRAK4 inhibition.<xref rid="ref75" ref-type="bibr"/>
</p></caption><graphic id="gr21" position="float" orientation="portrait" xlink:href="jm5c01641_0021.jpg"/></fig><p>Although less precedented, likely due to the scarcity
of methods
for the synthesis of disubstituted scaffolds, caged ring systems such
as BCPs, BCHs, BCHeps and cubanes, have potential as <italic toggle="yes">meta</italic>-substituted benzene bioisosteres. This was exemplified by Caldwell
et al. in the development of covalent Bruton&#8217;s tyrosine kinase
(BTK) inhibitors (<xref rid="fig22" ref-type="fig">Figure <xref rid="fig22" ref-type="fig"/>
</xref>).<xref rid="ref76" ref-type="bibr"/> To improve the aqueous solubility
and metabolic stability of acrylamide <bold>89</bold>, the authors
explored the replacement of the <italic toggle="yes">meta</italic>-substituted
benzene ring with alternative alkyl linkers. This was supported by
SAR and X-ray cocrystal structure data. Incorporation of a [2.1.1]&#173;BCH
linker (<bold>90</bold>) resulted in increased solubility and membrane
permeability, and lower hepatic clearance, concomitant with a small
reduction in inhibitory potency in both the enzyme and cell-based
assays. Further exploration of the linkers led to the discovery of
evobrutinib (<bold>91</bold>), a BTK inhibitor with higher solubility
and membrane permeability that was progressed to clinical trials.</p><fig position="float" id="fig22" fig-type="figure" orientation="portrait"><label>22</label><caption><p>Effect
of replacing a meta-substituted benzene ring with a [2.1.1]&#173;BCH
linker on BTK inhibition, solubility, hepatic clearance, and membrane
permeability. Structure of clinical candidate evobrutinib (<bold>91</bold>).<xref rid="ref76" ref-type="bibr"/>
</p></caption><graphic id="gr22" position="float" orientation="portrait" xlink:href="jm5c01641_0022.jpg"/></fig></sec><sec id="sec5.8"><title>Replacement of <italic toggle="yes">ortho</italic>-Substituted Benzene Rings</title><p>There are limited data available in ChEMBL on the application of <italic toggle="yes">ortho</italic>-substituted benzene bioisosteres. Our workflow showed
that 1,2-substituted cyclohexane and 1,2-substituted cyclohexene are
the replacements that lead to smallest changes in bioactivity, although
these effects were context dependent. The incorporation of a 1,2-substituted
cyclohexane was associated with an increase in solubility.</p><p>Kuduk
and co-workers aimed to replace the <italic toggle="yes">ortho-</italic>substituted
benzene ring in the bradykinin B<sub>1</sub> antagonist <bold>92</bold> with an alternative, nonaromatic scaffold to improve the physicochemical
properties of their compounds (<xref rid="fig23" ref-type="fig">Figure <xref rid="fig23" ref-type="fig"/>
</xref>).<xref rid="ref77" ref-type="bibr"/> Toward this
aim, compounds <bold>93</bold>&#8211;<bold>97</bold> were prepared.
The replacement of the <italic toggle="yes">ortho</italic>-substituted benzene
with a 1,2-substituted cyclohexene (<bold>93</bold>) or a bicyclo[2.2.1]&#173;heptane
(<bold>97</bold>) led to a significant reduction in inhibitory potency.
On the other hand, the 4,5-substituted cyclohexenes <bold>94</bold>&#8211;<bold>95</bold> and the <italic toggle="yes">trans</italic>-1,2-substituted
cyclohexane <bold>96</bold> showed improved binding affinity for the
bradykinin B1 receptor, although this was concomitant with increased
clearance <italic toggle="yes">in vivo</italic>. The authors speculated that the
nonaromatic nature of the methyl ester in <bold>94</bold> and <bold>96</bold> resulted in faster hydrolysis, responsible for their lower
metabolic stability compared to the <italic toggle="yes">ortho</italic>-substituted
benzene <bold>92</bold>.</p><fig position="float" id="fig23" fig-type="figure" orientation="portrait"><label>23</label><caption><p>Impact of the replacement of an ortho-substituted
benzene with
alternative nonaromatic scaffolds on antagonism of bradykinin B1 receptors,
Log<italic toggle="yes">P</italic>, and metabolic stability.<xref rid="ref77" ref-type="bibr"/>
</p></caption><graphic id="gr23" position="float" orientation="portrait" xlink:href="jm5c01641_0023.jpg"/></fig><p>Smaller rings, such as cyclopropanes
and cyclopentanes, can also
be used to replace <italic toggle="yes">ortho</italic>-substituted benzenes, as
demonstrated by Saleeb et al. in their development of inhibitors of <italic toggle="yes">Pseudomonas aeruginosa</italic> exoenzyme S ADP-ribosyltransferase
activity (<xref rid="fig24" ref-type="fig">Figure <xref rid="fig24" ref-type="fig"/>
</xref>).<xref rid="ref78" ref-type="bibr"/> In this example, the relative configuration
of the cyclopropane ring had a significant impact on bioactivity,
with the <italic toggle="yes">trans</italic> isomer <bold>99</bold> outperforming
the <italic toggle="yes">cis</italic>-isomer <bold>100</bold> by an order of magnitude.</p><fig position="float" id="fig24" fig-type="figure" orientation="portrait"><label>24</label><caption><p>Substitution
of an ortho-substituted benzene with cyclopropane
in inhibitors of <italic toggle="yes">Pseudomonas aeruginosa</italic> exoenzyme
S ADP-ribosyltransferase.<xref rid="ref78" ref-type="bibr"/>
</p></caption><graphic id="gr24" position="float" orientation="portrait" xlink:href="jm5c01641_0024.jpg"/></fig></sec></sec><sec id="sec6"><title>Summary and Outlook</title><p>In this perspective, we lay out
a strategy to mapping the bioisostere
landscape through a data-driven approach, exemplified by mapping benzene
bioisosteres. This allowed us to evaluate the context-dependency of
such bioisosteric substitutions while highlighting recent applications
and identifying areas that would benefit from further research. This
was achieved through the deployment of an open-access, data-mining
workflow (BioSTAR).</p><p>The data-mining analysis performed enabled
the ranking of 57 potential
benzene bioisosteres based on their impact on bioactivity, solubility
and clearance. We hope that these findings will assist practicing
medicinal chemists in prioritizing potential bioisosteric replacements
for benzene, and that the data-mining workflow employed will serve
as a valuable, general tool for the quantitative evaluation of molecular
replacements.</p><p>Examining the benzene bioisostere landscape revealed
areas with
limited available data, highlighting opportunities where additional
research could significantly benefit the community. For example, bioactivity
data for <italic toggle="yes">meta</italic>- and <italic toggle="yes">ortho</italic>-substituted
benzene bioisosteres remains particularly scarce. The development
of synthetic methodologies to access novel, and diversely functionalized
carbocyclic scaffolds is therefore essential to advance this field
and allow the evaluation of the impact of these replacements on bioactivity,
solubility, and ADME properties.</p><p>The findings of this data-mining
analysis are expected to evolve
as more data becomes available. In line with this, the workflow developed
only uses open-source software so others may reproduce and extend
this analysis over time or apply it to different open access or even
proprietary databases. Expanding this approach to include the extensive
bioactivity and molecular property data from pharmaceutical companies
holds great promise. A notable, relevant example is the work by Kramer
et al., who conducted a MMP analysis to extract absorption, distribution,
metabolism, elimination and toxicity (ADMET) knowledge from pooled
data shared by AstraZeneca, Genentech, and Roche.<xref rid="ref79" ref-type="bibr"/> This collaboration resulted in synergistic knowledge gains
without compromising intellectual property, as full molecular structures
were not disclosed. Applying a similar effort to bioactivity and bioisosterism
could yield equally promising results, advancing the field while preserving
proprietary information.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material id="sifile1" position="float" content-type="local-data" orientation="portrait"><media xlink:href="jm5c01641_si_001.pdf" position="float" orientation="portrait"/></supplementary-material></sec></body><back><bio id="BIO-d14e1587-autogenerated" rid="ath1"><p>
<bold>Pol Hern&#225;ndez-Llad&#243;</bold> is a Novo Nordisk
Postdoctoral Research Fellow at the University of Oxford, where he
develops chemical biology tools to identify and validate new therapeutic
targets for metabolic diseases. He obtained his undergraduate degree
in Chemistry from the University of Barcelona, which included a six-month
research stay at Imperial College London and a one-year industrial
placement in medicinal chemistry at GSK. He completed his DPhil in
synthetic organic chemistry at the University of Oxford in 2023, under
the supervision of Professor Jonathan W. Burton.</p></bio><bio id="BIO-d14e1591-autogenerated" rid="ath2"><p>
<bold>Nicholas A. Meanwell</bold> received his Ph.D.
from the University
of Sheffield and conducted postdoctoral studies at Wayne State University.
In a 40-year career at Bristol Myes Squibb, he was associated with
the invention of more than 30 clinical candidates including the HIV-1
attachment inhibitor fostemsavir and the HCV inhibitors asunaprevir,
daclatasvir, and beclabuvir. He was inducted into the <italic toggle="yes">ACS
Division of Medicinal Chemistry Hall of Fame</italic> in 2015. He
was the corecipient of ACS &#8220;<italic toggle="yes">Heroes of Chemistry</italic>&#8221; awards in 2017 and 2023 and was the recipient of the <italic toggle="yes">2022 Alfred Burger Award in Medicinal Chemistry</italic>. He received
the <italic toggle="yes">2024 Anton&#237;n Hol&#253; Memorial Award</italic>, the <italic toggle="yes">2025 ASPET Scientific Achievement in Drug Discovery
and Development Award</italic> and was named a <italic toggle="yes">Fellow of the
ACS</italic> in 2022.</p></bio><bio id="BIO-d14e1608-autogenerated" rid="ath3"><p>
<bold>Angela J.
Russell</bold> is Professor of Medicinal Chemistry
at the University of Oxford, working at the interface of chemistry,
biology, and medicine to discover small molecules that influence cell
fate for therapeutic use, particularly in degenerative diseases. She
earned her DPhil in Organic Chemistry from the University of Oxford
in 2004 under the joint supervision of Professor Steve Davies and
Dr Tim Perera. Her work has led to the creation of several spin&#8211;out
companies (MuOx, acquired by Summit Therapeutics, OxStem, and Kodiform
Therapeutics) and two clinical trials for Duchenne muscular dystrophy
(DMD) and COVID-19. She was a recipient of a <italic toggle="yes">Harrington Rare
Diseases Scholar Award</italic> (2020) and the <italic toggle="yes">Royal Society
of Chemistry&#8217;s Jeremy Knowles Award</italic> (2024) in recognition
of her work in DMD.</p></bio><notes id="notes-1" notes-type="si"><p>The Supporting Information
is available free of charge at <ext-link xlink:href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.5c01641?goto=supporting-info" ext-link-type="uri">https://pubs.acs.org/doi/10.1021/acs.jmedchem.5c01641</ext-link>.<list list-type="simple" id="silist"><list-item><p>Extended results of the
MMP analysis, analysis of the
impact of stereochemistry on bioactivity, correlation analysis between
compound properties and cLog<italic toggle="yes">P</italic>, and BioiSostere Analysis
and Ranking (BioSTAR) workflow user guide (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c01641/suppl_file/jm5c01641_si_001.pdf" ext-link-type="uri">PDF</ext-link>)</p></list-item></list>
</p></notes><notes id="notes-2" notes-type="author-contributions"><p>The manuscript
was written through contributions of all coauthors. All authors have
given approval of the final version of the manuscript.</p></notes><notes id="notes-3" notes-type="conflict-of-interest"><p>The authors
declare no competing financial interest.</p></notes><glossary><def-list specific-use="delimiter-char::" id="dl1"><title>Abbreviations
Used</title><def-item><term>ADME</term><def><p>absorption, distribution,
metabolism
and elimination</p></def></def-item><def-item><term>ADMET</term><def><p>absorption, distribution, metabolism, elimination and toxicity</p></def></def-item><def-item><term>ANOVA</term><def><p>analysis of variance</p></def></def-item><def-item><term>ATR</term><def><p>ataxia telangiectasia
mutated and Rad3 related</p></def></def-item><def-item><term>BCH</term><def><p>bicyclo&#173;[2.1.1]&#173;hexane</p></def></def-item><def-item><term>BCHep</term><def><p>bicyclo&#173;[3.1.1]&#173;heptane</p></def></def-item><def-item><term>BCO</term><def><p>bicyclo&#173;[2.2.2]&#173;octane</p></def></def-item><def-item><term>BCP</term><def><p>bicyclo&#173;[1.1.1]&#173;pentane</p></def></def-item><def-item><term>BioSTAR</term><def><p>BioiSosTere Analysis and Ranking</p></def></def-item><def-item><term>BTK</term><def><p>Bruton&#8217;s
tyrosine kinase</p></def></def-item><def-item><term>F+I</term><def><p>fragmentation and indexing algorithm</p></def></def-item><def-item><term>Fsp<sup>3</sup>
</term><def><p>the fraction of carbon atoms in
a molecule that are <italic toggle="yes">sp</italic>
<sup>3</sup> hybridized</p></def></def-item><def-item><term>IDO</term><def><p>indoleamine-2,3-dioxygenase</p></def></def-item><def-item><term>IRAK</term><def><p>interleukin-1
receptor-associated kinase</p></def></def-item><def-item><term>LTC4S</term><def><p>leukotriene C4 synthase</p></def></def-item><def-item><term>MCS</term><def><p>maximum common substructure</p></def></def-item><def-item><term>MDM</term><def><p>murine double minute</p></def></def-item><def-item><term>MMP</term><def><p>matched molecular pair</p></def></def-item><def-item><term>MAT2A</term><def><p>methionine adenosyltransferase
2A</p></def></def-item><def-item><term>MTAP</term><def><p>methylthioadenosine
phosphorylase</p></def></def-item><def-item><term>NHL</term><def><p>non-Hodgkin&#8217;s lymphoma</p></def></def-item><def-item><term>PDB</term><def><p>protein data bank</p></def></def-item><def-item><term>R/R T-PLL</term><def><p>relapsed/refractory T-cell prolymphocytic
leukemia</p></def></def-item><def-item><term>
<italic toggle="yes">T. brucei</italic>
</term><def><p>
<italic toggle="yes">Trypanosoma brucei</italic>
</p></def></def-item><def-item><term>THP</term><def><p>tetrahydropyran</p></def></def-item><def-item><term>TNKS</term><def><p>tankyrase</p></def></def-item><def-item><term>tPSA</term><def><p>topological polar surface
area</p></def></def-item></def-list></glossary><ref-list><ref id="ref1"><element-citation publication-type="journal" id="cit1"><name name-style="western"><surname>Lovering</surname><given-names>F.</given-names></name><name name-style="western"><surname>Bikker</surname><given-names>J.</given-names></name><name name-style="western"><surname>Humblet</surname><given-names>C.</given-names></name><article-title>Escape from
flatland: increasing
saturation as an approach to improving clinical success</article-title><source>J. Med. Chem.</source><year>2009</year><volume>52</volume><issue>21</issue><fpage>6752</fpage><lpage>6756</lpage><pub-id pub-id-type="doi">10.1021/jm901241e</pub-id><pub-id pub-id-type="pmid">19827778</pub-id></element-citation></ref><ref id="ref2"><element-citation publication-type="journal" id="cit2"><name name-style="western"><surname>Lovering</surname><given-names>F.</given-names></name><article-title>Escape from
flatland 2: complexity and promiscuity</article-title><source>MedChemComm</source><year>2013</year><volume>4</volume><issue>3</issue><fpage>515</fpage><lpage>519</lpage><pub-id pub-id-type="doi">10.1039/c2md20347b</pub-id></element-citation></ref><ref id="ref3"><element-citation publication-type="journal" id="cit3"><name name-style="western"><surname>Churcher</surname><given-names>I.</given-names></name><name name-style="western"><surname>Newbold</surname><given-names>S.</given-names></name><name name-style="western"><surname>Murray</surname><given-names>C. W.</given-names></name><article-title>Return
to flatland</article-title><source>Nat. Rev. Chem.</source><year>2025</year><volume>9</volume><issue>3</issue><fpage>140</fpage><lpage>141</lpage><pub-id pub-id-type="doi">10.1038/s41570-025-00688-5</pub-id><pub-id pub-id-type="pmid">39891023</pub-id></element-citation></ref><ref id="ref4"><element-citation publication-type="journal" id="cit4"><name name-style="western"><surname>Ritchie</surname><given-names>T. J.</given-names></name><name name-style="western"><surname>Macdonald</surname><given-names>S. J. F.</given-names></name><article-title>The
impact of aromatic ring count on compound developability
&#8211; are too many aromatic rings a liability in drug design?</article-title><source>Drug Discovery Today</source><year>2009</year><volume>14</volume><issue>21</issue><fpage>1011</fpage><lpage>1020</lpage><pub-id pub-id-type="doi">10.1016/j.drudis.2009.07.014</pub-id><pub-id pub-id-type="pmid">19729075</pub-id></element-citation></ref><ref id="ref5"><element-citation publication-type="journal" id="cit5"><name name-style="western"><surname>Leeson</surname><given-names>P. D.</given-names></name><name name-style="western"><surname>Bento</surname><given-names>A. P.</given-names></name><name name-style="western"><surname>Gaulton</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hersey</surname><given-names>A.</given-names></name><name name-style="western"><surname>Manners</surname><given-names>E. J.</given-names></name><name name-style="western"><surname>Radoux</surname><given-names>C. J.</given-names></name><name name-style="western"><surname>Leach</surname><given-names>A. R.</given-names></name><article-title>Target-based
evaluation of &#8220;drug-like&#8221;
properties and ligand efficiencies</article-title><source>J. Med.
Chem.</source><year>2021</year><volume>64</volume><issue>11</issue><fpage>7210</fpage><lpage>7230</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.1c00416</pub-id><pub-id pub-id-type="pmid">33983732</pub-id><pub-id pub-id-type="pmcid">PMC7610969</pub-id></element-citation></ref><ref id="ref6"><element-citation publication-type="journal" id="cit6"><name name-style="western"><surname>Shire</surname><given-names>B. R.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>E. A.</given-names></name><article-title>Conquering the synthesis and functionalization
of bicyclo[1.1.1]&#173;pentanes</article-title><source>JACS Au</source><year>2023</year><volume>3</volume><issue>6</issue><fpage>1539</fpage><lpage>1553</lpage><pub-id pub-id-type="doi">10.1021/jacsau.3c00014</pub-id><pub-id pub-id-type="pmid">37388694</pub-id><pub-id pub-id-type="pmcid">PMC10301682</pub-id></element-citation></ref><ref id="ref7"><element-citation publication-type="journal" id="cit7"><name name-style="western"><surname>Pellicciari</surname><given-names>R.</given-names></name><name name-style="western"><surname>Raimondo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Marinozzi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Natalini</surname><given-names>B.</given-names></name><name name-style="western"><surname>Costantino</surname><given-names>G.</given-names></name><name name-style="western"><surname>Thomsen</surname><given-names>C.</given-names></name><article-title>(S)-(+)-2-(3&#8216;-Carboxybicyclo&#173;[1.1.1]&#173;pentyl)-
glycine, a structurally new group I metabotropic glutamate receptor
antagonist</article-title><source>J. Med. Chem.</source><year>1996</year><volume>39</volume><issue>15</issue><fpage>2874</fpage><lpage>2876</lpage><pub-id pub-id-type="doi">10.1021/jm960254o</pub-id><pub-id pub-id-type="pmid">8709120</pub-id></element-citation></ref><ref id="ref8"><element-citation publication-type="journal" id="cit8"><name name-style="western"><surname>Stepan</surname><given-names>A. F.</given-names></name><name name-style="western"><surname>Subramanyam</surname><given-names>C.</given-names></name><name name-style="western"><surname>Efremov</surname><given-names>I. V.</given-names></name><name name-style="western"><surname>Dutra</surname><given-names>J. K.</given-names></name><name name-style="western"><surname>O&#8217;Sullivan</surname><given-names>T. J.</given-names></name><name name-style="western"><surname>DiRico</surname><given-names>K. J.</given-names></name><name name-style="western"><surname>McDonald</surname><given-names>W. S.</given-names></name><name name-style="western"><surname>Won</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dorff</surname><given-names>P. H.</given-names></name><name name-style="western"><surname>Nolan</surname><given-names>C. E.</given-names></name><name name-style="western"><surname>Becker</surname><given-names>S. L.</given-names></name><name name-style="western"><surname>Pustilnik</surname><given-names>L. R.</given-names></name><name name-style="western"><surname>Riddell</surname><given-names>D. R.</given-names></name><name name-style="western"><surname>Kauffman</surname><given-names>G. W.</given-names></name><name name-style="western"><surname>Kormos</surname><given-names>B. L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Capetta</surname><given-names>S. H.</given-names></name><name name-style="western"><surname>Green</surname><given-names>M. E.</given-names></name><name name-style="western"><surname>Karki</surname><given-names>K.</given-names></name><name name-style="western"><surname>Sibley</surname><given-names>E.</given-names></name><name name-style="western"><surname>Atchison</surname><given-names>K. P.</given-names></name><name name-style="western"><surname>Hallgren</surname><given-names>A. J.</given-names></name><name name-style="western"><surname>Oborski</surname><given-names>C. E.</given-names></name><name name-style="western"><surname>Robshaw</surname><given-names>A. E.</given-names></name><name name-style="western"><surname>Sneed</surname><given-names>B.</given-names></name><name name-style="western"><surname>O&#8217;Donnell</surname><given-names>C. J.</given-names></name><article-title>Application of the bicyclo[1.1.1]&#173;pentane
motif as a nonclassical phenyl ring bioisostere in the design of a
potent and orally active &#947;-secretase inhibitor</article-title><source>J. Med. Chem.</source><year>2012</year><volume>55</volume><issue>7</issue><fpage>3414</fpage><lpage>3424</lpage><pub-id pub-id-type="doi">10.1021/jm300094u</pub-id><pub-id pub-id-type="pmid">22420884</pub-id></element-citation></ref><ref id="ref9"><element-citation publication-type="journal" id="cit9"><name name-style="western"><surname>Reinhold</surname><given-names>M.</given-names></name><name name-style="western"><surname>Steinebach</surname><given-names>J.</given-names></name><name name-style="western"><surname>Golz</surname><given-names>C.</given-names></name><name name-style="western"><surname>Walker</surname><given-names>J. C. L.</given-names></name><article-title>Synthesis of
polysubstituted bicyclo[2.1.1]&#173;hexanes enabling access to new chemical
space</article-title><source>Chem. Sci.</source><year>2023</year><volume>14</volume><issue>36</issue><fpage>9885</fpage><lpage>9891</lpage><pub-id pub-id-type="doi">10.1039/D3SC03083K</pub-id><pub-id pub-id-type="pmid">37736652</pub-id><pub-id pub-id-type="pmcid">PMC10510755</pub-id></element-citation></ref><ref id="ref10"><element-citation publication-type="journal" id="cit10"><name name-style="western"><surname>Agasti</surname><given-names>S.</given-names></name><name name-style="western"><surname>Beltran</surname><given-names>F.</given-names></name><name name-style="western"><surname>Pye</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kaltsoyannis</surname><given-names>N.</given-names></name><name name-style="western"><surname>Crisenza</surname><given-names>G. E. M.</given-names></name><name name-style="western"><surname>Procter</surname><given-names>D. J.</given-names></name><article-title>A catalytic alkene
insertion approach
to bicyclo[2.1.1]&#173;hexane bioisosteres</article-title><source>Nat. Chem.</source><year>2023</year><volume>15</volume><issue>4</issue><fpage>535</fpage><lpage>541</lpage><pub-id pub-id-type="doi">10.1038/s41557-023-01135-y</pub-id><pub-id pub-id-type="pmid">36781910</pub-id></element-citation></ref><ref id="ref11"><element-citation publication-type="journal" id="cit11"><name name-style="western"><surname>Denisenko</surname><given-names>A.</given-names></name><name name-style="western"><surname>Garbuz</surname><given-names>P.</given-names></name><name name-style="western"><surname>Makovetska</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shablykin</surname><given-names>O.</given-names></name><name name-style="western"><surname>Lesyk</surname><given-names>D.</given-names></name><name name-style="western"><surname>Al-Maali</surname><given-names>G.</given-names></name><name name-style="western"><surname>Korzh</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sadkova</surname><given-names>I. V.</given-names></name><name name-style="western"><surname>Mykhailiuk</surname><given-names>P. K.</given-names></name><article-title>1,2-Disubstituted bicyclo[2.1.1]&#173;hexanes as saturated
bioisosteres of ortho-substituted benzene</article-title><source>Chem.
Sci.</source><year>2023</year><volume>14</volume><issue>48</issue><fpage>14092</fpage><lpage>14099</lpage><pub-id pub-id-type="doi">10.1039/D3SC05121H</pub-id><pub-id pub-id-type="pmid">38098705</pub-id><pub-id pub-id-type="pmcid">PMC10718076</pub-id></element-citation></ref><ref id="ref12"><element-citation publication-type="journal" id="cit12"><name name-style="western"><surname>Iida</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kanazawa</surname><given-names>J.</given-names></name><name name-style="western"><surname>Matsunaga</surname><given-names>T.</given-names></name><name name-style="western"><surname>Miyamoto</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hirano</surname><given-names>K.</given-names></name><name name-style="western"><surname>Uchiyama</surname><given-names>M.</given-names></name><article-title>Practical and facile access to bicyclo[3.1.1]&#173;heptanes:
potent bioisosteres of meta-substituted benzenes</article-title><source>J. Am. Chem. Soc.</source><year>2022</year><volume>144</volume><issue>48</issue><fpage>21848</fpage><lpage>21852</lpage><pub-id pub-id-type="doi">10.1021/jacs.2c09733</pub-id><pub-id pub-id-type="pmid">36342862</pub-id></element-citation></ref><ref id="ref13"><element-citation publication-type="journal" id="cit13"><name name-style="western"><surname>Frank</surname><given-names>N.</given-names></name><name name-style="western"><surname>Nugent</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shire</surname><given-names>B. R.</given-names></name><name name-style="western"><surname>Pickford</surname><given-names>H. D.</given-names></name><name name-style="western"><surname>Rabe</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sterling</surname><given-names>A. J.</given-names></name><name name-style="western"><surname>Zarganes-Tzitzikas</surname><given-names>T.</given-names></name><name name-style="western"><surname>Grimes</surname><given-names>T.</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>A. L.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>R. C.</given-names></name><name name-style="western"><surname>Schofield</surname><given-names>C. J.</given-names></name><name name-style="western"><surname>Brennan</surname><given-names>P. E.</given-names></name><name name-style="western"><surname>Duarte</surname><given-names>F.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>E. A.</given-names></name><article-title>Synthesis of meta-substituted
arene bioisosteres from
[3.1.1]&#173;propellane</article-title><source>Nature</source><year>2022</year><volume>611</volume><issue>7937</issue><fpage>721</fpage><lpage>726</lpage><pub-id pub-id-type="doi">10.1038/s41586-022-05290-z</pub-id><pub-id pub-id-type="pmid">36108675</pub-id></element-citation></ref><ref id="ref14"><element-citation publication-type="journal" id="cit14"><name name-style="western"><surname>Wiesenfeldt</surname><given-names>M. P.</given-names></name><name name-style="western"><surname>Rossi-Ashton</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Perry</surname><given-names>I. B.</given-names></name><name name-style="western"><surname>Diesel</surname><given-names>J.</given-names></name><name name-style="western"><surname>Garry</surname><given-names>O. L.</given-names></name><name name-style="western"><surname>Bartels</surname><given-names>F.</given-names></name><name name-style="western"><surname>Coote</surname><given-names>S. C.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yeung</surname><given-names>C. S.</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>D. J.</given-names></name><name name-style="western"><surname>MacMillan</surname><given-names>D. W. C.</given-names></name><article-title>General access to cubanes as benzene
bioisosteres</article-title><source>Nature</source><year>2023</year><volume>618</volume><issue>7965</issue><fpage>513</fpage><lpage>518</lpage><pub-id pub-id-type="doi">10.1038/s41586-023-06021-8</pub-id><pub-id pub-id-type="pmid">37015289</pub-id><pub-id pub-id-type="pmcid">PMC10680098</pub-id></element-citation></ref><ref id="ref15"><element-citation publication-type="journal" id="cit15"><name name-style="western"><surname>Chalmers</surname><given-names>B. A.</given-names></name><name name-style="western"><surname>Xing</surname><given-names>H.</given-names></name><name name-style="western"><surname>Houston</surname><given-names>S.</given-names></name><name name-style="western"><surname>Clark</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ghassabian</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kuo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>B.</given-names></name><name name-style="western"><surname>Reitsma</surname><given-names>A.</given-names></name><name name-style="western"><surname>Murray</surname><given-names>C.-E. P.</given-names></name><name name-style="western"><surname>Stok</surname><given-names>J. E.</given-names></name><name name-style="western"><surname>Boyle</surname><given-names>G. M.</given-names></name><name name-style="western"><surname>Pierce</surname><given-names>C. J.</given-names></name><name name-style="western"><surname>Littler</surname><given-names>S. W.</given-names></name><name name-style="western"><surname>Winkler</surname><given-names>D. A.</given-names></name><name name-style="western"><surname>Bernhardt</surname><given-names>P. V.</given-names></name><name name-style="western"><surname>Pasay</surname><given-names>C.</given-names></name><name name-style="western"><surname>De Voss</surname><given-names>J. J.</given-names></name><name name-style="western"><surname>McCarthy</surname><given-names>J.</given-names></name><name name-style="western"><surname>Parsons</surname><given-names>P. G.</given-names></name><name name-style="western"><surname>Walter</surname><given-names>G. H.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>M. T.</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>H. M.</given-names></name><name name-style="western"><surname>Nilsson</surname><given-names>S. K.</given-names></name><name name-style="western"><surname>Tsanaktsidis</surname><given-names>J.</given-names></name><name name-style="western"><surname>Savage</surname><given-names>G. P.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>C. M.</given-names></name><article-title>Validating
Eaton&#8217;s hypothesis: cubane as a benzene bioisostere</article-title><source>Angew. Chem., Int. Ed.</source><year>2016</year><volume>55</volume><issue>11</issue><fpage>3580</fpage><lpage>3585</lpage><pub-id pub-id-type="doi">10.1002/anie.201510675</pub-id><pub-id pub-id-type="pmid">26846616</pub-id></element-citation></ref><ref id="ref16"><element-citation publication-type="journal" id="cit16"><name name-style="western"><surname>Pellicciari</surname><given-names>R.</given-names></name><name name-style="western"><surname>Costantino</surname><given-names>G.</given-names></name><name name-style="western"><surname>Giovagnoni</surname><given-names>E.</given-names></name><name name-style="western"><surname>Mattoli</surname><given-names>L.</given-names></name><name name-style="western"><surname>Brabet</surname><given-names>I.</given-names></name><name name-style="western"><surname>Pin</surname><given-names>J.-P.</given-names></name><article-title>Synthesis
and preliminary evaluation of (S)-2-(4&#8242;-carboxycubyl)&#173;glycine,
a new selective mGluR1 antagonist</article-title><source>Bioorg. Med.
Chem. Lett.</source><year>1998</year><volume>8</volume><issue>12</issue><fpage>1569</fpage><lpage>1574</lpage><pub-id pub-id-type="doi">10.1016/S0960-894X(98)00265-0</pub-id><pub-id pub-id-type="pmid">9873392</pub-id></element-citation></ref><ref id="ref17"><element-citation publication-type="journal" id="cit17"><name name-style="western"><surname>Son</surname><given-names>J.-Y.</given-names></name><name name-style="western"><surname>Aikonen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Morgan</surname><given-names>N.</given-names></name><name name-style="western"><surname>Harmata</surname><given-names>A. S.</given-names></name><name name-style="western"><surname>Sabatini</surname><given-names>J. J.</given-names></name><name name-style="western"><surname>Sausa</surname><given-names>R. C.</given-names></name><name name-style="western"><surname>Byrd</surname><given-names>E. F. C.</given-names></name><name name-style="western"><surname>Ess</surname><given-names>D. H.</given-names></name><name name-style="western"><surname>Paton</surname><given-names>R. S.</given-names></name><name name-style="western"><surname>Stephenson</surname><given-names>C. R. J.</given-names></name><article-title>Exploring cuneanes as potential benzene
isosteres and
energetic materials: scope and mechanistic investigations into regioselective
rearrangements from cubanes</article-title><source>J. Am. Chem. Soc.</source><year>2023</year><volume>145</volume><issue>30</issue><fpage>16355</fpage><lpage>16364</lpage><pub-id pub-id-type="doi">10.1021/jacs.3c03226</pub-id><pub-id pub-id-type="pmid">37486221</pub-id><pub-id pub-id-type="pmcid">PMC10529534</pub-id></element-citation></ref><ref id="ref18"><element-citation publication-type="journal" id="cit18"><name name-style="western"><surname>Smith</surname><given-names>E.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>K. D.</given-names></name><name name-style="western"><surname>O&#8217;Brien</surname><given-names>L.</given-names></name><name name-style="western"><surname>Argent</surname><given-names>S. P.</given-names></name><name name-style="western"><surname>Salome</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lefebvre</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Valery</surname><given-names>A.</given-names></name><name name-style="western"><surname>B&#246;c&#252;</surname><given-names>M.</given-names></name><name name-style="western"><surname>Newton</surname><given-names>G. N.</given-names></name><name name-style="western"><surname>Lam</surname><given-names>H. W.</given-names></name><article-title>Silver&#173;(I)-catalyzed synthesis of
cuneanes from cubanes and their investigation as isosteres</article-title><source>J. Am. Chem. Soc.</source><year>2023</year><volume>145</volume><issue>30</issue><fpage>16365</fpage><lpage>16373</lpage><pub-id pub-id-type="doi">10.1021/jacs.3c03207</pub-id><pub-id pub-id-type="pmid">37478562</pub-id><pub-id pub-id-type="pmcid">PMC10401713</pub-id></element-citation></ref><ref id="ref19"><element-citation publication-type="journal" id="cit19"><name name-style="western"><surname>Fujiwara</surname><given-names>K.</given-names></name><name name-style="western"><surname>Nagasawa</surname><given-names>S.</given-names></name><name name-style="western"><surname>Maeyama</surname><given-names>R.</given-names></name><name name-style="western"><surname>Segawa</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hirasawa</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hirokawa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Iwabuchi</surname><given-names>Y.</given-names></name><article-title>Biological
evaluation of isosteric
applicability of 1,3-substituted cuneanes as m-substituted benzenes
enabled by selective isomerization of 1,4-substituted cubanes</article-title><source>Chem. - Eur. J.</source><year>2024</year><volume>30</volume><issue>11</issue><elocation-id>e202303548</elocation-id><pub-id pub-id-type="doi">10.1002/chem.202303548</pub-id><pub-id pub-id-type="pmid">38012076</pub-id></element-citation></ref><ref id="ref20"><element-citation publication-type="journal" id="cit20"><name name-style="western"><surname>Takebe</surname><given-names>H.</given-names></name><name name-style="western"><surname>Matsubara</surname><given-names>S.</given-names></name><article-title>Cuneanes as potential benzene bioisosteres having chirality</article-title><source>Synthesis</source><year>2025</year><volume>57</volume><issue>08</issue><fpage>1441</fpage><lpage>1447</lpage><pub-id pub-id-type="doi">10.1055/a-2403-1860</pub-id></element-citation></ref><ref id="ref21"><element-citation publication-type="journal" id="cit21"><name name-style="western"><surname>Smyrnov</surname><given-names>O. K.</given-names></name><name name-style="western"><surname>Melnykov</surname><given-names>K. P.</given-names></name><name name-style="western"><surname>Pashenko</surname><given-names>O. Y.</given-names></name><name name-style="western"><surname>Volochnyuk</surname><given-names>D. M.</given-names></name><name name-style="western"><surname>Ryabukhin</surname><given-names>S. V.</given-names></name><article-title>Stellane at the forefront: derivatization
and reactivity
studies of a promising saturated bioisostere of ortho-substituted
benzenes</article-title><source>Org. Lett.</source><year>2024</year><volume>26</volume><issue>22</issue><fpage>4808</fpage><lpage>4812</lpage><pub-id pub-id-type="doi">10.1021/acs.orglett.4c01645</pub-id><pub-id pub-id-type="pmid">38804566</pub-id></element-citation></ref><ref id="ref22"><element-citation publication-type="journal" id="cit22"><name name-style="western"><surname>Tsien</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Merchant</surname><given-names>R. R.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>T.</given-names></name><article-title>Three-dimensional saturated C&#173;(sp3)-rich
bioisosteres for benzene</article-title><source>Nat. Rev. Chem.</source><year>2024</year><volume>8</volume><issue>8</issue><fpage>605</fpage><lpage>627</lpage><pub-id pub-id-type="doi">10.1038/s41570-024-00623-0</pub-id><pub-id pub-id-type="pmid">38982260</pub-id><pub-id pub-id-type="pmcid">PMC11823177</pub-id></element-citation></ref><ref id="ref23"><element-citation publication-type="journal" id="cit23"><name name-style="western"><surname>Subbaiah</surname><given-names>M. A. M.</given-names></name><name name-style="western"><surname>Meanwell</surname><given-names>N. A.</given-names></name><article-title>Bioisosteres of the phenyl ring: recent strategic applications
in lead optimization and drug design</article-title><source>J. Med.
Chem.</source><year>2021</year><volume>64</volume><issue>19</issue><fpage>14046</fpage><lpage>14128</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.1c01215</pub-id><pub-id pub-id-type="pmid">34591488</pub-id></element-citation></ref><ref id="ref24"><element-citation publication-type="journal" id="cit24"><name name-style="western"><surname>Nagasawa</surname><given-names>S.</given-names></name><name name-style="western"><surname>Iwabuchi</surname><given-names>Y.</given-names></name><article-title>Recent progress in accessing multi-functionalized
caged
hydrocarbons: en route to highly functionalized saturated (bio)&#173;isosteres
of benzene rings</article-title><source>Synthesis</source><year>2024</year><volume>57</volume><issue>6</issue><fpage>1153</fpage><lpage>1170</lpage></element-citation></ref><ref id="ref25"><element-citation publication-type="journal" id="cit25"><name name-style="western"><surname>Mykhailiuk</surname><given-names>P. K.</given-names></name><article-title>Saturated
bioisosteres of benzene: where to go next?</article-title><source>Org. Biomol. Chem.</source><year>2019</year><volume>17</volume><issue>11</issue><fpage>2839</fpage><lpage>2849</lpage><pub-id pub-id-type="doi">10.1039/C8OB02812E</pub-id><pub-id pub-id-type="pmid">30672560</pub-id></element-citation></ref><ref id="ref26"><element-citation publication-type="journal" id="cit26"><name name-style="western"><surname>Diepers</surname><given-names>H. E.</given-names></name><name name-style="western"><surname>Walker</surname><given-names>J. C. L.</given-names></name><article-title>(Bio)&#173;isosteres
of ortho- and meta-substituted benzenes</article-title><source>Beilstein
J. Org. Chem.</source><year>2024</year><volume>20</volume><fpage>859</fpage><lpage>890</lpage><pub-id pub-id-type="doi">10.3762/bjoc.20.78</pub-id><pub-id pub-id-type="pmid">38655554</pub-id><pub-id pub-id-type="pmcid">PMC11035989</pub-id></element-citation></ref><ref id="ref27"><element-citation publication-type="journal" id="cit27"><name name-style="western"><surname>Langmuir</surname><given-names>I.</given-names></name><article-title>Isomorphism,
isosterism and covalence</article-title><source>J. Am. Chem. Soc.</source><year>1919</year><volume>41</volume><issue>10</issue><fpage>1543</fpage><lpage>1559</lpage><pub-id pub-id-type="doi">10.1021/ja02231a009</pub-id></element-citation></ref><ref id="ref28"><element-citation publication-type="journal" id="cit28"><name name-style="western"><surname>Burger</surname><given-names>A.</given-names></name><article-title>Isosterism
and bioisosterism in drug design</article-title><source>Prog. Drug
Res.</source><year>1991</year><issue>37</issue><fpage>287</fpage><lpage>371</lpage><pub-id pub-id-type="doi">10.1007/978-3-0348-7139-6_7</pub-id><pub-id pub-id-type="pmid">1763185</pub-id></element-citation></ref><ref id="ref29"><element-citation publication-type="journal" id="cit29"><name name-style="western"><surname>Erlenmeyer</surname><given-names>H.</given-names></name><name name-style="western"><surname>Leo</surname><given-names>M.</given-names></name><article-title>&#220;ber pseudoatome</article-title><source>Helv. Chim. Acta</source><year>1932</year><volume>15</volume><issue>1</issue><fpage>1171</fpage><lpage>1186</lpage><pub-id pub-id-type="doi">10.1002/hlca.193201501132</pub-id></element-citation></ref><ref id="ref30"><mixed-citation publication-type="book" id="cit30"><person-group person-group-type="allauthors"><string-name name-style="western"><surname>Friedman</surname>, <given-names>H. L.</given-names></string-name></person-group><article-title>Influence of
isosteric replacements upon biological ctivity</article-title>. In <source>First Symposium on Chemical-Biological Correlation</source>; <publisher-name>National Academy of Sciences, National Research Council</publisher-name>: <publisher-loc>Washington D.C.</publisher-loc>, <year>1950</year><pub-id pub-id-type="doi">10.17226/18474</pub-id>.</mixed-citation></ref><ref id="ref31"><element-citation publication-type="journal" id="cit31"><name name-style="western"><surname>Thornber</surname><given-names>C. W.</given-names></name><article-title>Isosterism
and molecular modification in drug design</article-title><source>Chem.
Soc. Rev.</source><year>1979</year><volume>8</volume><issue>4</issue><fpage>563</fpage><lpage>580</lpage><pub-id pub-id-type="doi">10.1039/cs9790800563</pub-id></element-citation></ref><ref id="ref32"><element-citation publication-type="journal" id="cit32"><name name-style="western"><surname>Seddon</surname><given-names>M. P.</given-names></name><name name-style="western"><surname>Cosgrove</surname><given-names>D. A.</given-names></name><name name-style="western"><surname>Gillet</surname><given-names>V. J.</given-names></name><article-title>Bioisosteric replacements extracted
from high-quality structures in the protein databank</article-title><source>ChemMedChem</source><year>2018</year><volume>13</volume><issue>6</issue><fpage>607</fpage><lpage>613</lpage><pub-id pub-id-type="doi">10.1002/cmdc.201700679</pub-id><pub-id pub-id-type="pmid">29314719</pub-id></element-citation></ref><ref id="ref33"><mixed-citation publication-type="book" id="cit33"><person-group person-group-type="allauthors"><string-name name-style="western"><surname>Brown</surname>, <given-names>N.</given-names></string-name></person-group><article-title>Bioisosteres and
scaffolds</article-title>. In <source>In silico medicinal chemistry:
computational methods to support drug design</source>; <person-group person-group-type="editor"><string-name name-style="western"><surname>Brown</surname>, <given-names>N.</given-names></string-name></person-group>, Ed.; <publisher-name>The Royal
Society of Chemistry</publisher-name>, <year>2015</year>; pp <fpage>112</fpage>&#8211;<lpage>123</lpage>.</mixed-citation></ref><ref id="ref34"><mixed-citation publication-type="book" id="cit34"><person-group person-group-type="allauthors"><string-name name-style="western"><surname>Fujita</surname>, <given-names>T.</given-names></string-name>; <string-name name-style="western"><surname>Adachi</surname>, <given-names>M.</given-names></string-name>; <string-name name-style="western"><surname>Akamatsu</surname>, <given-names>M.</given-names></string-name>; <string-name name-style="western"><surname>Asao</surname>, <given-names>M.</given-names></string-name>; <string-name name-style="western"><surname>Fukami</surname>, <given-names>H.</given-names></string-name>; <string-name name-style="western"><surname>Inoue</surname>, <given-names>Y.</given-names></string-name>; <string-name name-style="western"><surname>Iwataki</surname>, <given-names>I.</given-names></string-name>; <string-name name-style="western"><surname>Kido</surname>, <given-names>M.</given-names></string-name>; <string-name name-style="western"><surname>Koga</surname>, <given-names>H.</given-names></string-name>; <string-name name-style="western"><surname>Kobayashi</surname>, <given-names>T.</given-names></string-name>; <string-name name-style="western"><surname>Kumita</surname>, <given-names>I.</given-names></string-name>; <string-name name-style="western"><surname>Makino</surname>, <given-names>K.</given-names></string-name>; <string-name name-style="western"><surname>Oda</surname>, <given-names>K.</given-names></string-name>; <string-name name-style="western"><surname>Ogino</surname>, <given-names>A.</given-names></string-name>; <string-name name-style="western"><surname>Ohta</surname>, <given-names>M.</given-names></string-name>; <string-name name-style="western"><surname>Sakamoto</surname>, <given-names>F.</given-names></string-name>; <string-name name-style="western"><surname>Sekiya</surname>, <given-names>T.</given-names></string-name>; <string-name name-style="western"><surname>Shimizu</surname>, <given-names>R.</given-names></string-name>; <string-name name-style="western"><surname>Takayama</surname>, <given-names>C.</given-names></string-name>; <string-name name-style="western"><surname>Tada</surname>, <given-names>Y.</given-names></string-name>; <string-name name-style="western"><surname>Ueda</surname>, <given-names>I.</given-names></string-name>; <string-name name-style="western"><surname>Umeda</surname>, <given-names>Y.</given-names></string-name>; <string-name name-style="western"><surname>Yamakawa</surname>, <given-names>M.</given-names></string-name>; <string-name name-style="western"><surname>Yamaura</surname>, <given-names>Y.</given-names></string-name>; <string-name name-style="western"><surname>Yoshioka</surname>, <given-names>H.</given-names></string-name>; <string-name name-style="western"><surname>Yoshida</surname>, <given-names>M.</given-names></string-name>; <string-name name-style="western"><surname>Yoshimoto</surname>, <given-names>M.</given-names></string-name>; <string-name name-style="western"><surname>Wakabayashi</surname>, <given-names>K.</given-names></string-name></person-group><article-title>Background and features of emil, a system for database-aided
bioanalogous structural transformation of bioactive compounds</article-title>. In. In <source>Pharmacochemistry Library</source>; <person-group person-group-type="editor"><string-name name-style="western"><surname>Fujita</surname>, <given-names>T.</given-names></string-name></person-group>, Ed.; <publisher-name>Elsevier</publisher-name>, <year>1995</year>; Vol. <volume>23</volume>, pp <fpage>235</fpage>&#8211;<lpage>273</lpage>.</mixed-citation></ref><ref id="ref35"><element-citation publication-type="journal" id="cit35"><name name-style="western"><surname>Ujv&#225;ry</surname><given-names>I.</given-names></name><article-title>Extended Summary:
BIOSTER&#58872;a database of structurally analogous compounds</article-title><source>Pestic. Sci.</source><year>1997</year><volume>51</volume><issue>1</issue><fpage>92</fpage><lpage>95</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/(SICI)1096-9063(199709)51:1&amp;#x0003c;92::AID-PS608&amp;#x0003e;3.0.CO;2-9</pub-id></element-citation></ref><ref id="ref36"><element-citation publication-type="journal" id="cit36"><name name-style="western"><surname>Sheridan</surname><given-names>R. P.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>M. D.</given-names></name><article-title>A method for visualizing
recurrent topological substructures
in sets of active molecules</article-title><source>J. Chem. Inf. Comput.
Sci.</source><year>1998</year><volume>38</volume><issue>5</issue><fpage>915</fpage><lpage>924</lpage><pub-id pub-id-type="doi">10.1021/ci980044f</pub-id></element-citation></ref><ref id="ref37"><element-citation publication-type="journal" id="cit37"><name name-style="western"><surname>Hussain</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rea</surname><given-names>C.</given-names></name><article-title>Computationally efficient algorithm to identify matched molecular
pairs (MMPs) in large data sets</article-title><source>J. Chem. Inf.
Model.</source><year>2010</year><volume>50</volume><issue>3</issue><fpage>339</fpage><lpage>348</lpage><pub-id pub-id-type="doi">10.1021/ci900450m</pub-id><pub-id pub-id-type="pmid">20121045</pub-id></element-citation></ref><ref id="ref38"><element-citation publication-type="journal" id="cit38"><name name-style="western"><surname>Cuozzo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Daina</surname><given-names>A.</given-names></name><name name-style="western"><surname>Perez</surname><given-names>M. A. S.</given-names></name><name name-style="western"><surname>Michielin</surname><given-names>O.</given-names></name><name name-style="western"><surname>Zoete</surname><given-names>V.</given-names></name><article-title>SwissBioisostere 2021: updated structural, bioactivity and physicochemical
data delivered by a reshaped web interface</article-title><source>Nucleic Acids Res.</source><year>2022</year><volume>50</volume><issue>D1</issue><fpage>D1382</fpage><lpage>D1390</lpage><pub-id pub-id-type="doi">10.1093/nar/gkab1047</pub-id><pub-id pub-id-type="pmid">34788840</pub-id><pub-id pub-id-type="pmcid">PMC8728117</pub-id></element-citation></ref><ref id="ref39"><element-citation publication-type="journal" id="cit39"><name name-style="western"><surname>Wirth</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zoete</surname><given-names>V.</given-names></name><name name-style="western"><surname>Michielin</surname><given-names>O.</given-names></name><name name-style="western"><surname>Sauer</surname><given-names>W. H. B.</given-names></name><article-title>SwissBioisostere:
a database of molecular replacements for ligand design</article-title><source>Nucleic Acids Res.</source><year>2013</year><volume>41</volume><issue>D1</issue><fpage>D1137</fpage><lpage>D1143</lpage><pub-id pub-id-type="doi">10.1093/nar/gks1059</pub-id><pub-id pub-id-type="pmid">23161688</pub-id><pub-id pub-id-type="pmcid">PMC3531158</pub-id></element-citation></ref><ref id="ref40"><element-citation publication-type="journal" id="cit40"><name name-style="western"><surname>Ertl</surname><given-names>P.</given-names></name><name name-style="western"><surname>Altmann</surname><given-names>E.</given-names></name><name name-style="western"><surname>Racine</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>R.</given-names></name><article-title>Ring replacement recommender:
ring modifications for improving biological activity</article-title><source>Eur. J. Med. Chem.</source><year>2022</year><volume>238</volume><elocation-id>114483</elocation-id><pub-id pub-id-type="doi">10.1016/j.ejmech.2022.114483</pub-id><pub-id pub-id-type="pmid">35635950</pub-id></element-citation></ref><ref id="ref41"><element-citation publication-type="journal" id="cit41"><name name-style="western"><surname>Kennewell</surname><given-names>E. A.</given-names></name><name name-style="western"><surname>Willett</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ducrot</surname><given-names>P.</given-names></name><name name-style="western"><surname>Luttmann</surname><given-names>C.</given-names></name><article-title>Identification
of target-specific
bioisosteric fragments from ligand&#8211;protein crystallographic
data</article-title><source>J. Comput. Aided Mol. Des.</source><year>2006</year><volume>20</volume><issue>6</issue><fpage>385</fpage><lpage>394</lpage><pub-id pub-id-type="doi">10.1007/s10822-006-9072-0</pub-id><pub-id pub-id-type="pmid">17058118</pub-id></element-citation></ref><ref id="ref42"><element-citation publication-type="journal" id="cit42"><name name-style="western"><surname>Desaphy</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rognan</surname><given-names>D.</given-names></name><article-title>sc-PDB-Frag: A database
of protein&#8211;ligand interaction
patterns for bioisosteric replacements</article-title><source>J. Chem.
Inf. Model.</source><year>2014</year><volume>54</volume><issue>7</issue><fpage>1908</fpage><lpage>1918</lpage><pub-id pub-id-type="doi">10.1021/ci500282c</pub-id><pub-id pub-id-type="pmid">24991975</pub-id></element-citation></ref><ref id="ref200"><mixed-citation publication-type="database" id="cit200">The
BioSTAR (BioiSosTere Analysis and Ranking) tool can be accessed via
the KNIME Hub at: <uri xlink:href="https://hub.knime.com/s/5Ns3wwqRutwZl3y0">https://hub.knime.com/s/5Ns3wwqRutwZl3y0</uri>.</mixed-citation></ref><ref id="ref43"><element-citation publication-type="journal" id="cit43"><name name-style="western"><surname>Sander</surname><given-names>T.</given-names></name><name name-style="western"><surname>Freyss</surname><given-names>J.</given-names></name><name name-style="western"><surname>von Korff</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rufener</surname><given-names>C.</given-names></name><article-title>DataWarrior: an open-source
program for chemistry aware data visualization and analysis</article-title><source>J. Chem. Inf. Model.</source><year>2015</year><volume>55</volume><issue>2</issue><fpage>460</fpage><lpage>473</lpage><pub-id pub-id-type="doi">10.1021/ci500588j</pub-id><pub-id pub-id-type="pmid">25558886</pub-id></element-citation></ref><ref id="ref44"><element-citation publication-type="journal" id="cit44"><name name-style="western"><surname>Kramer</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fuchs</surname><given-names>J. E.</given-names></name><name name-style="western"><surname>Whitebread</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gedeck</surname><given-names>P.</given-names></name><name name-style="western"><surname>Liedl</surname><given-names>K. R.</given-names></name><article-title>Matched
Molecular Pair analysis: significance and the impact of experimental
uncertainty</article-title><source>J. Med. Chem.</source><year>2014</year><volume>57</volume><issue>9</issue><fpage>3786</fpage><lpage>3802</lpage><pub-id pub-id-type="doi">10.1021/jm500317a</pub-id><pub-id pub-id-type="pmid">24738976</pub-id></element-citation></ref><ref id="ref45"><mixed-citation publication-type="other" id="cit45"><article-title>The calculation
was performed on 12th Gen Intel&#173;(R) Core&#173;(TM) i5&#8211;12500, 3000
MHz, 6 Core(s), 12 Logical Processor(s)</article-title>.</mixed-citation></ref><ref id="ref46"><element-citation publication-type="journal" id="cit46"><name name-style="western"><surname>Ritchie</surname><given-names>T. J.</given-names></name><name name-style="western"><surname>Macdonald</surname><given-names>S. J. F.</given-names></name><article-title>Heterocyclic replacements for benzene:
maximising ADME
benefits by considering individual ring isomers</article-title><source>Eur. J. Med. Chem.</source><year>2016</year><volume>124</volume><fpage>1057</fpage><lpage>1068</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2016.10.029</pub-id><pub-id pub-id-type="pmid">27783976</pub-id></element-citation></ref><ref id="ref47"><element-citation publication-type="journal" id="cit47"><name name-style="western"><surname>Gunaydin</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bartberger</surname><given-names>M. D.</given-names></name><article-title>Stacking with no planarity?</article-title><source>ACS Med. Chem. Lett.</source><year>2016</year><volume>7</volume><issue>4</issue><fpage>341</fpage><lpage>344</lpage><pub-id pub-id-type="doi">10.1021/acsmedchemlett.6b00099</pub-id><pub-id pub-id-type="pmid">27096037</pub-id><pub-id pub-id-type="pmcid">PMC4834644</pub-id></element-citation></ref><ref id="ref48"><element-citation publication-type="journal" id="cit48"><name name-style="western"><surname>Levterov</surname><given-names>V. V.</given-names></name><name name-style="western"><surname>Panasyuk</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Pivnytska</surname><given-names>V. O.</given-names></name><name name-style="western"><surname>Mykhailiuk</surname><given-names>P. K.</given-names></name><article-title>Water-soluble
non-classical benzene mimetics</article-title><source>Angew. Chem.,
Int. Ed.</source><year>2020</year><volume>59</volume><issue>18</issue><fpage>7161</fpage><lpage>7167</lpage><pub-id pub-id-type="doi">10.1002/anie.202000548</pub-id><pub-id pub-id-type="pmid">32060990</pub-id></element-citation></ref><ref id="ref49"><element-citation publication-type="journal" id="cit49"><name name-style="western"><surname>Denisenko</surname><given-names>A.</given-names></name><name name-style="western"><surname>Garbuz</surname><given-names>P.</given-names></name><name name-style="western"><surname>Shishkina</surname><given-names>S. V.</given-names></name><name name-style="western"><surname>Voloshchuk</surname><given-names>N. M.</given-names></name><name name-style="western"><surname>Mykhailiuk</surname><given-names>P. K.</given-names></name><article-title>Saturated bioisosteres of ortho-substituted benzenes</article-title><source>Angew. Chem., Int. Ed.</source><year>2020</year><volume>59</volume><issue>46</issue><fpage>20515</fpage><lpage>20521</lpage><pub-id pub-id-type="doi">10.1002/anie.202004183</pub-id><pub-id pub-id-type="pmid">32662201</pub-id></element-citation></ref><ref id="ref50"><element-citation publication-type="journal" id="cit50"><name name-style="western"><surname>Ferenczy</surname><given-names>G. G.</given-names></name><name name-style="western"><surname>Keser&#369;</surname><given-names>G. M.</given-names></name><article-title>Thermodynamics
guided lead discovery and optimization</article-title><source>Drug
Discovery Today</source><year>2010</year><volume>15</volume><issue>21</issue><fpage>919</fpage><lpage>932</lpage><pub-id pub-id-type="doi">10.1016/j.drudis.2010.08.013</pub-id><pub-id pub-id-type="pmid">20801227</pub-id></element-citation></ref><ref id="ref51"><element-citation publication-type="journal" id="cit51"><name name-style="western"><surname>Hann</surname><given-names>M. M.</given-names></name><article-title>Molecular
obesity, potency and other addictions in drug discovery</article-title><source>MedChemComm</source><year>2011</year><volume>2</volume><issue>5</issue><fpage>349</fpage><lpage>355</lpage><pub-id pub-id-type="doi">10.1039/C1MD00017A</pub-id></element-citation></ref><ref id="ref52"><element-citation publication-type="journal" id="cit52"><name name-style="western"><surname>Ishikawa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hashimoto</surname><given-names>Y.</given-names></name><article-title>Improvement in aqueous solubility in small molecule
drug discovery programs by disruption of molecular planarity and symmetry</article-title><source>J. Med. Chem.</source><year>2011</year><volume>54</volume><issue>6</issue><fpage>1539</fpage><lpage>1554</lpage><pub-id pub-id-type="doi">10.1021/jm101356p</pub-id><pub-id pub-id-type="pmid">21344906</pub-id></element-citation></ref><ref id="ref53"><element-citation publication-type="journal" id="cit53"><name name-style="western"><surname>Nicolaou</surname><given-names>K. C.</given-names></name><name name-style="western"><surname>Vourloumis</surname><given-names>D.</given-names></name><name name-style="western"><surname>Totokotsopoulos</surname><given-names>S.</given-names></name><name name-style="western"><surname>Papakyriakou</surname><given-names>A.</given-names></name><name name-style="western"><surname>Karsunky</surname><given-names>H.</given-names></name><name name-style="western"><surname>Fernando</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gavrilyuk</surname><given-names>J.</given-names></name><name name-style="western"><surname>Webb</surname><given-names>D.</given-names></name><name name-style="western"><surname>Stepan</surname><given-names>A. F.</given-names></name><article-title>Synthesis and biopharmaceutical
evaluation
of imatinib analogues featuring unusual structural motifs</article-title><source>ChemMedChem</source><year>2016</year><volume>11</volume><issue>1</issue><fpage>31</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1002/cmdc.201500510</pub-id><pub-id pub-id-type="pmid">26585829</pub-id></element-citation></ref><ref id="ref54"><element-citation publication-type="journal" id="cit54"><name name-style="western"><surname>Yardley-Jones</surname><given-names>A.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>D.</given-names></name><name name-style="western"><surname>Parke</surname><given-names>D. V.</given-names></name><article-title>The toxicity of benzene and its metabolism
and molecular pathology in human risk assessment</article-title><source>Br. J. Ind. Med.</source><year>1991</year><volume>48</volume><issue>7</issue><fpage>437</fpage><lpage>444</lpage><pub-id pub-id-type="doi">10.1136/oem.48.7.437</pub-id><pub-id pub-id-type="pmid">1854646</pub-id><pub-id pub-id-type="pmcid">PMC1035396</pub-id></element-citation></ref><ref id="ref55"><element-citation publication-type="journal" id="cit55"><name name-style="western"><surname>Kitamura</surname><given-names>N.</given-names></name><name name-style="western"><surname>Sacco</surname><given-names>M. D.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Townsend</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Meng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ba</surname><given-names>M.</given-names></name><name name-style="western"><surname>Szeto</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kukuljac</surname><given-names>A.</given-names></name><name name-style="western"><surname>Marty</surname><given-names>M. T.</given-names></name><name name-style="western"><surname>Schultz</surname><given-names>D.</given-names></name><name name-style="western"><surname>Cherry</surname><given-names>S.</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><article-title>Expedited
approach toward the rational design of noncovalent SARS-CoV-2 main
protease inhibitors</article-title><source>J. Med. Chem.</source><year>2022</year><volume>65</volume><issue>4</issue><fpage>2848</fpage><lpage>2865</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.1c00509</pub-id><pub-id pub-id-type="pmid">33891389</pub-id><pub-id pub-id-type="pmcid">PMC8536799</pub-id></element-citation></ref><ref id="ref56"><element-citation publication-type="journal" id="cit56"><name name-style="western"><surname>Charrier</surname><given-names>J.-D.</given-names></name><name name-style="western"><surname>Durrant</surname><given-names>S. J.</given-names></name><name name-style="western"><surname>Golec</surname><given-names>J. M. C.</given-names></name><name name-style="western"><surname>Kay</surname><given-names>D. P.</given-names></name><name name-style="western"><surname>Knegtel</surname><given-names>R. M. A.</given-names></name><name name-style="western"><surname>MacCormick</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mortimore</surname><given-names>M.</given-names></name><name name-style="western"><surname>O&#8217;Donnell</surname><given-names>M. E.</given-names></name><name name-style="western"><surname>Pinder</surname><given-names>J. L.</given-names></name><name name-style="western"><surname>Reaper</surname><given-names>P. M.</given-names></name><name name-style="western"><surname>Rutherford</surname><given-names>A. P.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>P. S. H.</given-names></name><name name-style="western"><surname>Young</surname><given-names>S. C.</given-names></name><name name-style="western"><surname>Pollard</surname><given-names>J. R.</given-names></name><article-title>Discovery of potent
and selective inhibitors of ataxia telangiectasia mutated and Rad3
related (ATR) protein kinase as potential anticancer agents</article-title><source>J. Med. Chem.</source><year>2011</year><volume>54</volume><issue>7</issue><fpage>2320</fpage><lpage>2330</lpage><pub-id pub-id-type="doi">10.1021/jm101488z</pub-id><pub-id pub-id-type="pmid">21413798</pub-id></element-citation></ref><ref id="ref57"><mixed-citation publication-type="book" id="cit57"><person-group person-group-type="allauthors"><string-name name-style="western"><surname>Young</surname>, <given-names>R. J.</given-names></string-name></person-group><article-title>Tactics to
Improve Solubility</article-title>. In <source>The medicinal chemist&#8217;s
guide to solving ADMET challenges</source>; <person-group person-group-type="editor"><string-name name-style="western"><surname>Schnider</surname>, <given-names>P.</given-names></string-name></person-group>, Ed.; <publisher-name>The Royal
Society of Chemistry</publisher-name>, <year>2021</year>; pp <fpage>16</fpage>&#8211;<lpage>35</lpage>.</mixed-citation></ref><ref id="ref58"><element-citation publication-type="journal" id="cit58"><name name-style="western"><surname>Tear</surname><given-names>W. F.</given-names></name><name name-style="western"><surname>Bag</surname><given-names>S.</given-names></name><name name-style="western"><surname>Diaz-Gonzalez</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ceballos-P&#233;rez</surname><given-names>G.</given-names></name><name name-style="western"><surname>Rojas-Barros</surname><given-names>D. I.</given-names></name><name name-style="western"><surname>Cordon-Obras</surname><given-names>C.</given-names></name><name name-style="western"><surname>P&#233;rez-Moreno</surname><given-names>G.</given-names></name><name name-style="western"><surname>Garc&#237;a-Hern&#225;ndez</surname><given-names>R.</given-names></name><name name-style="western"><surname>Martinez-Martinez</surname><given-names>M. S.</given-names></name><name name-style="western"><surname>Ruiz-Perez</surname><given-names>L. M.</given-names></name><name name-style="western"><surname>Gamarro</surname><given-names>F.</given-names></name><name name-style="western"><surname>Gonzalez Pacanowska</surname><given-names>D.</given-names></name><name name-style="western"><surname>Caffrey</surname><given-names>C. R.</given-names></name><name name-style="western"><surname>Ferrins</surname><given-names>L.</given-names></name><name name-style="western"><surname>Manzano</surname><given-names>P.</given-names></name><name name-style="western"><surname>Navarro</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pollastri</surname><given-names>M. P.</given-names></name><article-title>Selectivity and physicochemical optimization of repurposed
pyrazolo&#173;[1,5-b]&#173;pyridazines for the treatment of human african trypanosomiasis</article-title><source>J. Med. Chem.</source><year>2020</year><volume>63</volume><issue>2</issue><fpage>756</fpage><lpage>783</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.9b01741</pub-id><pub-id pub-id-type="pmid">31846577</pub-id><pub-id pub-id-type="pmcid">PMC6985937</pub-id></element-citation></ref><ref id="ref59"><element-citation publication-type="journal" id="cit59"><name name-style="western"><surname>Konteatis</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Travins</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gross</surname><given-names>S.</given-names></name><name name-style="western"><surname>Marjon</surname><given-names>K.</given-names></name><name name-style="western"><surname>Barnett</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mandley</surname><given-names>E.</given-names></name><name name-style="western"><surname>Nicolay</surname><given-names>B.</given-names></name><name name-style="western"><surname>Nagaraja</surname><given-names>R.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>W.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kalev</surname><given-names>P.</given-names></name><name name-style="western"><surname>Hyer</surname><given-names>M. L.</given-names></name><name name-style="western"><surname>DeLaBarre</surname><given-names>B.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Padyana</surname><given-names>A. K.</given-names></name><name name-style="western"><surname>Dang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Murtie</surname><given-names>J.</given-names></name><name name-style="western"><surname>Biller</surname><given-names>S. A.</given-names></name><name name-style="western"><surname>Sui</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Marks</surname><given-names>K. M.</given-names></name><article-title>Discovery
of AG-270, a first-in-class oral MAT2A inhibitor for the treatment
of tumors with homozygous MTAP deletion</article-title><source>J.
Med. Chem.</source><year>2021</year><volume>64</volume><issue>8</issue><fpage>4430</fpage><lpage>4449</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.0c01895</pub-id><pub-id pub-id-type="pmid">33829783</pub-id></element-citation></ref><ref id="ref60"><element-citation publication-type="journal" id="cit60"><name name-style="western"><surname>Roecker</surname><given-names>A. J.</given-names></name><name name-style="western"><surname>Layton</surname><given-names>M. E.</given-names></name><name name-style="western"><surname>Pero</surname><given-names>J. E.</given-names></name><name name-style="western"><surname>Kelly</surname><given-names>M. J.</given-names><suffix>III</suffix></name><name name-style="western"><surname>Greshock</surname><given-names>T. J.</given-names></name><name name-style="western"><surname>Kraus</surname><given-names>R. L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Klein</surname><given-names>R.</given-names></name><name name-style="western"><surname>Clements</surname><given-names>M.</given-names></name><name name-style="western"><surname>Daley</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jovanovska</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ballard</surname><given-names>J. E.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>F.</given-names></name><name name-style="western"><surname>Brunskill</surname><given-names>A. P. J.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>H.</given-names></name><name name-style="western"><surname>Houghton</surname><given-names>A. K.</given-names></name><name name-style="western"><surname>Burgey</surname><given-names>C. S.</given-names></name><article-title>Discovery of arylsulfonamide Nav1.7 inhibitors: IVIVC,
MPO methods, and optimization of selectivity profile</article-title><source>ACS Med. Chem. Lett.</source><year>2021</year><volume>12</volume><issue>6</issue><fpage>1038</fpage><lpage>1049</lpage><pub-id pub-id-type="doi">10.1021/acsmedchemlett.1c00218</pub-id><pub-id pub-id-type="pmid">34141090</pub-id><pub-id pub-id-type="pmcid">PMC8201757</pub-id></element-citation></ref><ref id="ref61"><element-citation publication-type="journal" id="cit61"><name name-style="western"><surname>Roy</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Vom</surname><given-names>A.</given-names></name><name name-style="western"><surname>Okamoto</surname><given-names>T.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>B. J.</given-names></name><name name-style="western"><surname>Birkinshaw</surname><given-names>R. W.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Abdo</surname><given-names>H.</given-names></name><name name-style="western"><surname>White</surname><given-names>C. A.</given-names></name><name name-style="western"><surname>Segal</surname><given-names>D.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>D. C. S.</given-names></name><name name-style="western"><surname>Baell</surname><given-names>J. B.</given-names></name><name name-style="western"><surname>Colman</surname><given-names>P. M.</given-names></name><name name-style="western"><surname>Czabotar</surname><given-names>P. E.</given-names></name><name name-style="western"><surname>Lessene</surname><given-names>G.</given-names></name><article-title>Structure-guided development
of potent benzoylurea
inhibitors of BCL-XL and BCL-2</article-title><source>J. Med. Chem.</source><year>2021</year><volume>64</volume><issue>9</issue><fpage>5447</fpage><lpage>5469</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.0c01771</pub-id><pub-id pub-id-type="pmid">33904752</pub-id></element-citation></ref><ref id="ref62"><element-citation publication-type="journal" id="cit62"><name name-style="western"><surname>Tse</surname><given-names>E. G.</given-names></name><name name-style="western"><surname>Houston</surname><given-names>S. D.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>C. M.</given-names></name><name name-style="western"><surname>Savage</surname><given-names>G. P.</given-names></name><name name-style="western"><surname>Rendina</surname><given-names>L. M.</given-names></name><name name-style="western"><surname>Hallyburton</surname><given-names>I.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>R.</given-names></name><name name-style="western"><surname>Walker</surname><given-names>G. S.</given-names></name><name name-style="western"><surname>Obach</surname><given-names>R. S.</given-names></name><name name-style="western"><surname>Todd</surname><given-names>M. H.</given-names></name><article-title>Nonclassical phenyl bioisosteres
as effective replacements in a series of novel open-source antimalarials</article-title><source>J. Med. Chem.</source><year>2020</year><volume>63</volume><issue>20</issue><fpage>11585</fpage><lpage>11601</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.0c00746</pub-id><pub-id pub-id-type="pmid">32678591</pub-id></element-citation></ref><ref id="ref63"><element-citation publication-type="journal" id="cit63"><name name-style="western"><surname>Thomas</surname><given-names>M. G.</given-names></name><name name-style="western"><surname>De Rycker</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ajakane</surname><given-names>M.</given-names></name><name name-style="western"><surname>Crouch</surname><given-names>S. D.</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>L.</given-names></name><name name-style="western"><surname>Daugan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fra</surname><given-names>G.</given-names></name><name name-style="western"><surname>Guerrero</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mackenzie</surname><given-names>C. J.</given-names></name><name name-style="western"><surname>MacLean</surname><given-names>L.</given-names></name><name name-style="western"><surname>Manthri</surname><given-names>S.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>F.</given-names></name><name name-style="western"><surname>Norval</surname><given-names>S.</given-names></name><name name-style="western"><surname>Osuna-Cabello</surname><given-names>M.</given-names></name><name name-style="western"><surname>Riley</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shishikura</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Miguel-Siles</surname><given-names>J.</given-names></name><name name-style="western"><surname>Simeons</surname><given-names>F. R. C.</given-names></name><name name-style="western"><surname>Stojanovski</surname><given-names>L.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>J.</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>S.</given-names></name><name name-style="western"><surname>Velasco</surname><given-names>R. F.</given-names></name><name name-style="western"><surname>Fiandor</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Wyatt</surname><given-names>P. G.</given-names></name><name name-style="western"><surname>Read</surname><given-names>K. D.</given-names></name><name name-style="western"><surname>Gilbert</surname><given-names>I. H.</given-names></name><name name-style="western"><surname>Miles</surname><given-names>T. J.</given-names></name><article-title>Identification
of 6-amino-1H-pyrazolo&#173;[3,4-d]&#173;pyrimidines with in vivo efficacy against
visceral leishmaniasis</article-title><source>RSC Med. Chem.</source><year>2020</year><volume>11</volume><issue>10</issue><fpage>1168</fpage><lpage>1177</lpage><pub-id pub-id-type="doi">10.1039/D0MD00203H</pub-id><pub-id pub-id-type="pmid">33479621</pub-id><pub-id pub-id-type="pmcid">PMC7651859</pub-id></element-citation></ref><ref id="ref64"><element-citation publication-type="journal" id="cit64"><name name-style="western"><surname>Huang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Guzman-Perez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Acquaviva</surname><given-names>L.</given-names></name><name name-style="western"><surname>Berry</surname><given-names>V.</given-names></name><name name-style="western"><surname>Bregman</surname><given-names>H.</given-names></name><name name-style="western"><surname>Dovey</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gunaydin</surname><given-names>H.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Saffran</surname><given-names>D.</given-names></name><name name-style="western"><surname>Serafino</surname><given-names>R.</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>C.</given-names></name><name name-style="western"><surname>DiMauro</surname><given-names>E. F.</given-names></name><article-title>Structure-based
design of 2-aminopyridine
oxazolidinones as potent and selective tankyrase inhibitors</article-title><source>ACS Med. Chem. Lett.</source><year>2013</year><volume>4</volume><issue>12</issue><fpage>1218</fpage><lpage>1223</lpage><pub-id pub-id-type="doi">10.1021/ml4003315</pub-id><pub-id pub-id-type="pmid">24900633</pub-id><pub-id pub-id-type="pmcid">PMC4027438</pub-id></element-citation></ref><ref id="ref65"><element-citation publication-type="journal" id="cit65"><name name-style="western"><surname>Pu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>M.</given-names></name><name name-style="western"><surname>Doty</surname><given-names>A. C.</given-names></name><name name-style="western"><surname>Ferguson</surname><given-names>H.</given-names></name><name name-style="western"><surname>Fradera</surname><given-names>X.</given-names></name><name name-style="western"><surname>Lesburg</surname><given-names>C. A.</given-names></name><name name-style="western"><surname>McGowan</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>J. R.</given-names></name><name name-style="western"><surname>Geda</surname><given-names>P.</given-names></name><name name-style="western"><surname>Song</surname><given-names>X.</given-names></name><name name-style="western"><surname>Otte</surname><given-names>K.</given-names></name><name name-style="western"><surname>Sciammetta</surname><given-names>N.</given-names></name><name name-style="western"><surname>Solban</surname><given-names>N.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Sloman</surname><given-names>D. L.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lammens</surname><given-names>A.</given-names></name><name name-style="western"><surname>Neumann</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>D. J.</given-names></name><name name-style="western"><surname>Pasternak</surname><given-names>A.</given-names></name><name name-style="western"><surname>Han</surname><given-names>Y.</given-names></name><article-title>Discovery of potent and orally available
bicyclo[1.1.1]&#173;pentane-derived indoleamine-2,3-dioxygenase 1 (IDO1)
inhibitors</article-title><source>ACS Med. Chem. Lett.</source><year>2020</year><volume>11</volume><issue>8</issue><fpage>1548</fpage><lpage>1554</lpage><pub-id pub-id-type="doi">10.1021/acsmedchemlett.0c00195</pub-id><pub-id pub-id-type="pmid">32832022</pub-id><pub-id pub-id-type="pmcid">PMC7429971</pub-id></element-citation></ref><ref id="ref66"><element-citation publication-type="journal" id="cit66"><name name-style="western"><surname>Aguilar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Du</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bernard</surname><given-names>D.</given-names></name><name name-style="western"><surname>McEachern</surname><given-names>D.</given-names></name><name name-style="western"><surname>Przybranowski</surname><given-names>S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>B.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zhai</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><article-title>Discovery of 4-((3&#8242;R,4&#8242;S,5&#8242;R)-6&#8243;-chloro-4&#8242;-(3-chloro-2-fluorophenyl)-1&#8242;-ethyl-2&#8243;-oxodispiro&#173;[cyclohexane-1,2&#8242;-pyrrolidine-3&#8242;,3&#8243;-indoline]-5&#8242;-carboxamido)&#173;bicyclo[2.2.2]&#173;octane-1-carboxylic
Acid (AA-115/APG-115): a potent and orally active Murine Double Minute
2 (MDM2) inhibitor in clinical development</article-title><source>J. Med. Chem.</source><year>2017</year><volume>60</volume><issue>7</issue><fpage>2819</fpage><lpage>2839</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.6b01665</pub-id><pub-id pub-id-type="pmid">28339198</pub-id><pub-id pub-id-type="pmcid">PMC5394527</pub-id></element-citation></ref><ref id="ref67"><mixed-citation publication-type="weblink" id="cit67"><article-title>A phase IIa study evaluating the pharmacokinetics,
safety and efficacy
of APG-115 as a single agent or in combination with APG-2575 in subjects
with relapsed/refractory T-cell prolymphocytic leukemia (R/R T-PLL)
or non-Hodgkin&#8217;s lymphoma (NHL)</article-title>, <year>2020</year>. <uri xlink:href="https://clinicaltrials.gov/study/NCT04496349">https://clinicaltrials.gov/study/NCT04496349</uri> (accessed April 11, 2025).</mixed-citation></ref><ref id="ref68"><element-citation publication-type="journal" id="cit68"><name name-style="western"><surname>Swidorski</surname><given-names>J. J.</given-names></name><name name-style="western"><surname>Jenkins</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hanumegowda</surname><given-names>U.</given-names></name><name name-style="western"><surname>Parker</surname><given-names>D. D.</given-names></name><name name-style="western"><surname>Beno</surname><given-names>B. R.</given-names></name><name name-style="western"><surname>Protack</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ng</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>A.</given-names></name><name name-style="western"><surname>Shanmugam</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Dicker</surname><given-names>I. B.</given-names></name><name name-style="western"><surname>Krystal</surname><given-names>M.</given-names></name><name name-style="western"><surname>Meanwell</surname><given-names>N. A.</given-names></name><name name-style="western"><surname>Regueiro-Ren</surname><given-names>A.</given-names></name><article-title>Design and
exploration of C-3 benzoic acid bioisosteres and alkyl replacements
in the context of GSK3532795 (BMS-955176) that exhibit broad spectrum
HIV-1 maturation inhibition</article-title><source>Bioorg. Med. Chem.
Lett.</source><year>2021</year><volume>36</volume><elocation-id>127823</elocation-id><pub-id pub-id-type="doi">10.1016/j.bmcl.2021.127823</pub-id><pub-id pub-id-type="pmid">33508465</pub-id></element-citation></ref><ref id="ref69"><element-citation publication-type="journal" id="cit69"><name name-style="western"><surname>Regueiro-Ren</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sit</surname><given-names>S.-Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Swidorski</surname><given-names>J. J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Venables</surname><given-names>B. L.</given-names></name><name name-style="western"><surname>Sin</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hartz</surname><given-names>R. A.</given-names></name><name name-style="western"><surname>Protack</surname><given-names>T.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>D.-R.</given-names></name><name name-style="western"><surname>Li</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kempson</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rampulla</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mathur</surname><given-names>A.</given-names></name><name name-style="western"><surname>Park</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sarjeant</surname><given-names>A.</given-names></name><name name-style="western"><surname>Benitex</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Rahematpura</surname><given-names>S.</given-names></name><name name-style="western"><surname>Parker</surname><given-names>D.</given-names></name><name name-style="western"><surname>Phillips</surname><given-names>T.</given-names></name><name name-style="western"><surname>Haskell</surname><given-names>R.</given-names></name><name name-style="western"><surname>Jenkins</surname><given-names>S.</given-names></name><name name-style="western"><surname>Santone</surname><given-names>K. S.</given-names></name><name name-style="western"><surname>Cockett</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hanumegowda</surname><given-names>U.</given-names></name><name name-style="western"><surname>Dicker</surname><given-names>I.</given-names></name><name name-style="western"><surname>Meanwell</surname><given-names>N. A.</given-names></name><name name-style="western"><surname>Krystal</surname><given-names>M.</given-names></name><article-title>The discovery of GSK3640254,
a next-generation inhibitor of HIV-1 maturation</article-title><source>J. Med. Chem.</source><year>2022</year><volume>65</volume><issue>18</issue><fpage>11927</fpage><lpage>11948</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.2c00879</pub-id><pub-id pub-id-type="pmid">36044257</pub-id></element-citation></ref><ref id="ref70"><element-citation publication-type="journal" id="cit70"><name name-style="western"><surname>Sit</surname><given-names>S.-Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Venables</surname><given-names>B. L.</given-names></name><name name-style="western"><surname>Swidorski</surname><given-names>J. J.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sin</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hartz</surname><given-names>R. A.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>D.-R.</given-names></name><name name-style="western"><surname>Li</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kempson</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Shanmugam</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Parker</surname><given-names>D.</given-names></name><name name-style="western"><surname>Jenkins</surname><given-names>S.</given-names></name><name name-style="western"><surname>Simmermacher</surname><given-names>J.</given-names></name><name name-style="western"><surname>Falk</surname><given-names>P.</given-names></name><name name-style="western"><surname>McAuliffe</surname><given-names>B.</given-names></name><name name-style="western"><surname>Cockett</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hanumegowda</surname><given-names>U.</given-names></name><name name-style="western"><surname>Dicker</surname><given-names>I.</given-names></name><name name-style="western"><surname>Krystal</surname><given-names>M.</given-names></name><name name-style="western"><surname>Meanwell</surname><given-names>N. A.</given-names></name><name name-style="western"><surname>Regueiro-Ren</surname><given-names>A.</given-names></name><article-title>Invention
of VH-937, a potent HIV-1 maturation inhibitor with the potential
for infrequent oral dosing in humans</article-title><source>ACS Med.
Chem. Lett.</source><year>2024</year><volume>15</volume><issue>11</issue><fpage>1997</fpage><lpage>2004</lpage><pub-id pub-id-type="doi">10.1021/acsmedchemlett.4c00419</pub-id><pub-id pub-id-type="pmid">39563829</pub-id><pub-id pub-id-type="pmcid">PMC11571082</pub-id></element-citation></ref><ref id="ref71"><element-citation publication-type="journal" id="cit71"><name name-style="western"><surname>Klug</surname><given-names>D. M.</given-names></name><name name-style="western"><surname>Mavrogiannaki</surname><given-names>E. M.</given-names></name><name name-style="western"><surname>Forbes</surname><given-names>K. C.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>L.</given-names></name><name name-style="western"><surname>Diaz-Gonzalez</surname><given-names>R.</given-names></name><name name-style="western"><surname>P&#233;rez-Moreno</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ceballos-P&#233;rez</surname><given-names>G.</given-names></name><name name-style="western"><surname>Garcia-Hern&#225;ndez</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bosch-Navarrete</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cord&#243;n-Obras</surname><given-names>C.</given-names></name><name name-style="western"><surname>G&#243;mez-Li&#241;&#225;n</surname><given-names>C.</given-names></name><name name-style="western"><surname>Saura</surname><given-names>A.</given-names></name><name name-style="western"><surname>Momper</surname><given-names>J. D.</given-names></name><name name-style="western"><surname>Martinez-Martinez</surname><given-names>M. S.</given-names></name><name name-style="western"><surname>Manzano</surname><given-names>P.</given-names></name><name name-style="western"><surname>Syed</surname><given-names>A.</given-names></name><name name-style="western"><surname>El-Sakkary</surname><given-names>N.</given-names></name><name name-style="western"><surname>Caffrey</surname><given-names>C. R.</given-names></name><name name-style="western"><surname>Gamarro</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ruiz-Perez</surname><given-names>L. M.</given-names></name><name name-style="western"><surname>Gonzalez Pacanowska</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ferrins</surname><given-names>L.</given-names></name><name name-style="western"><surname>Navarro</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pollastri</surname><given-names>M. P.</given-names></name><article-title>Lead optimization
of 3,5-disubstituted-7-azaindoles for the treatment of human African
trypanosomiasis</article-title><source>J. Med. Chem.</source><year>2021</year><volume>64</volume><issue>13</issue><fpage>9404</fpage><lpage>9430</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.1c00674</pub-id><pub-id pub-id-type="pmid">34156862</pub-id><pub-id pub-id-type="pmcid">PMC8412142</pub-id></element-citation></ref><ref id="ref72"><element-citation publication-type="journal" id="cit72"><name name-style="western"><surname>Alford</surname><given-names>J. S.</given-names></name><name name-style="western"><surname>Lampe</surname><given-names>J. W.</given-names></name><name name-style="western"><surname>Brach</surname><given-names>D.</given-names></name><name name-style="western"><surname>Chesworth</surname><given-names>R.</given-names></name><name name-style="western"><surname>Cosmopoulos</surname><given-names>K.</given-names></name><name name-style="western"><surname>Duncan</surname><given-names>K. W.</given-names></name><name name-style="western"><surname>Eckley</surname><given-names>S. T.</given-names></name><name name-style="western"><surname>Kutok</surname><given-names>J. L.</given-names></name><name name-style="western"><surname>Raimondi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Riera</surname><given-names>T. V.</given-names></name><name name-style="western"><surname>Shook</surname><given-names>B.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Totman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Farrow</surname><given-names>N. A.</given-names></name><article-title>Conformational-design-driven discovery
of EZM0414: a selective, potent SETD2 inhibitor for clinical studies</article-title><source>ACS Med. Chem. Lett.</source><year>2022</year><volume>13</volume><issue>7</issue><fpage>1137</fpage><lpage>1143</lpage><pub-id pub-id-type="doi">10.1021/acsmedchemlett.2c00167</pub-id><pub-id pub-id-type="pmid">35859865</pub-id><pub-id pub-id-type="pmcid">PMC9290024</pub-id></element-citation></ref><ref id="ref73"><element-citation publication-type="journal" id="cit73"><name name-style="western"><surname>Munck
af Rosensch&#246;ld</surname><given-names>M.</given-names></name><name name-style="western"><surname>Johannesson</surname><given-names>P.</given-names></name><name name-style="western"><surname>Nikitidis</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tyrchan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>H.-F.</given-names></name><name name-style="western"><surname>R&#246;nn</surname><given-names>R.</given-names></name><name name-style="western"><surname>Chapman</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ullah</surname><given-names>V.</given-names></name><name name-style="western"><surname>Nikitidis</surname><given-names>G.</given-names></name><name name-style="western"><surname>Glader</surname><given-names>P.</given-names></name><name name-style="western"><surname>K&#228;ck</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bonn</surname><given-names>B.</given-names></name><name name-style="western"><surname>W&#229;gberg</surname><given-names>F.</given-names></name><name name-style="western"><surname>Bj&#246;rkstrand</surname><given-names>E.</given-names></name><name name-style="western"><surname>Andersson</surname><given-names>U.</given-names></name><name name-style="western"><surname>Swedin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Rohman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Andreasson</surname><given-names>T.</given-names></name><name name-style="western"><surname>Bergstr&#246;m</surname><given-names>E. L.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>X.-H.</given-names></name><name name-style="western"><surname>Lundqvist</surname><given-names>A. J.</given-names></name><name name-style="western"><surname>Malmberg</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ek</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>E.</given-names></name><name name-style="western"><surname>Pettersen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ripa</surname><given-names>L.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>A. M.</given-names></name><article-title>Discovery of the
oral leukotriene C4 synthase inhibitor (1S,2S)-2-({5-[(5-chloro-2,4-difluorophenyl)&#173;(2-fluoro-2-methylpropyl)&#173;amino]-3-methoxypyrazin-2-yl}&#173;carbonyl)&#173;cyclopropanecarboxylic
acid (AZD9898) as a new treatment for asthma</article-title><source>J. Med. Chem.</source><year>2019</year><volume>62</volume><issue>17</issue><fpage>7769</fpage><lpage>7787</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.9b00555</pub-id><pub-id pub-id-type="pmid">31415176</pub-id></element-citation></ref><ref id="ref74"><element-citation publication-type="journal" id="cit74"><name name-style="western"><surname>Betts</surname><given-names>J.</given-names></name><name name-style="western"><surname>Larsson</surname><given-names>B.</given-names></name><name name-style="western"><surname>Jauhiainen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hegelund-Myrb&#228;ck</surname><given-names>T.</given-names></name><name name-style="western"><surname>Leander</surname><given-names>J.</given-names></name><name name-style="western"><surname>Berton</surname><given-names>A.</given-names></name><name name-style="western"><surname>Glader</surname><given-names>P.</given-names></name><name name-style="western"><surname>Aurell Holmberg</surname><given-names>A.</given-names></name><name name-style="western"><surname>Santisteban</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Franz&#233;n</surname><given-names>J.</given-names></name><name name-style="western"><surname>Albayaty</surname><given-names>M.</given-names></name><name name-style="western"><surname>Keen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kristensson</surname><given-names>C.</given-names></name><article-title>P138 Urinary
leukotriene E4 (uLTE4) pharmacodynamic
biomarker for early decision making in the AZD9898 adaptive phase
i study</article-title><source>Thorax</source><year>2018</year><volume>73</volume><issue>Suppl 4</issue><fpage>A177</fpage></element-citation></ref><ref id="ref75"><mixed-citation publication-type="other" id="cit75"><person-group person-group-type="allauthors"><string-name name-style="western"><surname>Santella</surname>, <given-names>J. B.</given-names></string-name>; <string-name name-style="western"><surname>Kumar</surname>, <given-names>S. R.</given-names></string-name>; <string-name name-style="western"><surname>Duncia</surname>, <given-names>J. V.</given-names></string-name>; <string-name name-style="western"><surname>Gardner</surname>, <given-names>D. S.</given-names></string-name>; <string-name name-style="western"><surname>Paidi</surname>, <given-names>V. R.</given-names></string-name>; <string-name name-style="western"><surname>Nair</surname>, <given-names>S. K.</given-names></string-name>; <string-name name-style="western"><surname>Wu</surname>, <given-names>J.
H.</given-names></string-name>; <string-name name-style="western"><surname>Murugesan</surname>, <given-names>N.</given-names></string-name>; <string-name name-style="western"><surname>Sarkunam</surname>, <given-names>K.</given-names></string-name>; <string-name name-style="western"><surname>Arunachalam</surname>, <given-names>P.</given-names></string-name></person-group><article-title>Heteroaryl substituted
nicotinamide compounds</article-title>, <year>2015</year>.</mixed-citation></ref><ref id="ref76"><element-citation publication-type="journal" id="cit76"><name name-style="western"><surname>Caldwell</surname><given-names>R. D.</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Askew</surname><given-names>B. C.</given-names></name><name name-style="western"><surname>Bender</surname><given-names>A. T.</given-names></name><name name-style="western"><surname>Brugger</surname><given-names>N.</given-names></name><name name-style="western"><surname>Camps</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dhanabal</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dutt</surname><given-names>V.</given-names></name><name name-style="western"><surname>Eichhorn</surname><given-names>T.</given-names></name><name name-style="western"><surname>Gardberg</surname><given-names>A. S.</given-names></name><name name-style="western"><surname>Goutopoulos</surname><given-names>A.</given-names></name><name name-style="western"><surname>Grenningloh</surname><given-names>R.</given-names></name><name name-style="western"><surname>Head</surname><given-names>J.</given-names></name><name name-style="western"><surname>Healey</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hodous</surname><given-names>B. L.</given-names></name><name name-style="western"><surname>Huck</surname><given-names>B. R.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>T. L.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>R. C.</given-names></name><name name-style="western"><surname>Mochalkin</surname><given-names>I.</given-names></name><name name-style="western"><surname>Morandi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>N.</given-names></name><name name-style="western"><surname>Meyring</surname><given-names>M.</given-names></name><name name-style="western"><surname>Potnick</surname><given-names>J. R.</given-names></name><name name-style="western"><surname>Santos</surname><given-names>D. C.</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sherer</surname><given-names>B.</given-names></name><name name-style="western"><surname>Shutes</surname><given-names>A.</given-names></name><name name-style="western"><surname>Urbahns</surname><given-names>K.</given-names></name><name name-style="western"><surname>Follis</surname><given-names>A. V.</given-names></name><name name-style="western"><surname>Wegener</surname><given-names>A. A.</given-names></name><name name-style="western"><surname>Zimmerli</surname><given-names>S. C.</given-names></name><name name-style="western"><surname>Liu-Bujalski</surname><given-names>L.</given-names></name><article-title>Discovery
of evobrutinib: an oral, potent, and highly selective, covalent Bruton&#8217;s
Tyrosine Kinase (BTK) Inhibitor for the treatment of immunological
diseases</article-title><source>J. Med. Chem.</source><year>2019</year><volume>62</volume><issue>17</issue><fpage>7643</fpage><lpage>7655</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.9b00794</pub-id><pub-id pub-id-type="pmid">31368705</pub-id></element-citation></ref><ref id="ref77"><element-citation publication-type="journal" id="cit77"><name name-style="western"><surname>Kuduk</surname><given-names>S. D.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>R. K.</given-names></name><name name-style="western"><surname>Ng</surname><given-names>C.</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>K. L.</given-names></name><name name-style="western"><surname>Ransom</surname><given-names>R. W.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Prueksaritanont</surname><given-names>T.</given-names></name><name name-style="western"><surname>Freidinger</surname><given-names>R. M.</given-names></name><name name-style="western"><surname>Pettibone</surname><given-names>D. J.</given-names></name><name name-style="western"><surname>Bock</surname><given-names>M. G.</given-names></name><article-title>Bradykinin B1 antagonists:
SAR studies
in the 2,3-diaminopyridine series</article-title><source>Bioorg. Med.
Chem. Lett.</source><year>2005</year><volume>15</volume><issue>17</issue><fpage>3925</fpage><lpage>3929</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2005.05.133</pub-id><pub-id pub-id-type="pmid">15993596</pub-id></element-citation></ref><ref id="ref78"><element-citation publication-type="journal" id="cit78"><name name-style="western"><surname>Saleeb</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sundin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Aglar</surname><given-names>&#214;.</given-names></name><name name-style="western"><surname>Pinto</surname><given-names>A. F.</given-names></name><name name-style="western"><surname>Ebrahimi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Forsberg</surname><given-names>&#197;.</given-names></name><name name-style="western"><surname>Sch&#252;ler</surname><given-names>H.</given-names></name><name name-style="western"><surname>Elofsson</surname><given-names>M.</given-names></name><article-title>Structure&#8211;activity
relationships for inhibitors of Pseudomonas aeruginosa exoenzyme S
ADP-ribosyltransferase activity</article-title><source>Eur. J. Med.
Chem.</source><year>2018</year><volume>143</volume><fpage>568</fpage><lpage>576</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2017.11.036</pub-id><pub-id pub-id-type="pmid">29207339</pub-id></element-citation></ref><ref id="ref79"><element-citation publication-type="journal" id="cit79"><name name-style="western"><surname>Kramer</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ting</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hert</surname><given-names>J.</given-names></name><name name-style="western"><surname>Schindler</surname><given-names>T.</given-names></name><name name-style="western"><surname>Stahl</surname><given-names>M.</given-names></name><name name-style="western"><surname>Robb</surname><given-names>G.</given-names></name><name name-style="western"><surname>Crawford</surname><given-names>J. J.</given-names></name><name name-style="western"><surname>Blaney</surname><given-names>J.</given-names></name><name name-style="western"><surname>Montague</surname><given-names>S.</given-names></name><name name-style="western"><surname>Leach</surname><given-names>A. G.</given-names></name><name name-style="western"><surname>Dossetter</surname><given-names>A. G.</given-names></name><name name-style="western"><surname>Griffen</surname><given-names>E. J.</given-names></name><article-title>Learning medicinal chemistry Absorption, Distribution,
Metabolism, Excretion, and Toxicity (ADMET) rules from cross-company
Matched Molecular Pairs Analysis (MMPA)</article-title><source>J.
Med. Chem.</source><year>2018</year><volume>61</volume><issue>8</issue><fpage>3277</fpage><lpage>3292</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.7b00935</pub-id><pub-id pub-id-type="pmid">28956609</pub-id></element-citation></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>